Intermediates and methods of compounds for degrading EGFR kinases
By conjugating EGFR inhibitors with E3 ligase ligands, the problem of difficulty in degrading multiple EGFR mutant proteins in the prior art is solved, effective degradation of EGFR mutant proteins is achieved, and drug resistance is potentially overcome Sexual disorders provide a new treatment for EGFR-related diseases.
Patent Information
- Application Number
- CN202410696695.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-31
- Filing Date
- 2024-05-31
- Publication Date
- 2024-12-03
AI Technical Summary
Existing EGFR-targeted PROTACs are difficult to effectively degrade a variety of EGFR mutant proteins, including Del19, L858R, Del19/T790M, L858R/T790M, Del19/T790M/C797S, and L858R/T790M/C797S, making it difficult to overcome drug resistance disorders.
Develop a novel bifunctional compound formed by conjugation of the EGFR inhibitor moiety and the E3 ligase ligand moiety for recruiting the target protein to the E3 ubiquitin ligase for degradation, with the specific compound structure of formula (X) or its Derivatives, used to treat diseases affected by EGFR regulation.
The compound is able to effectively recruit and degrade a variety of EGFR mutant proteins, potentially overcoming drug resistance disorders, and provides a new treatment for serious diseases, especially for EGFR-related cancers.
Smart Images

Figure BDA0004869953090000041 
Figure BDA0004869953090000072 
Figure BDA0004869953090000073
Abstract
Description
Technical Field
[0001] Disclosed herein are novel bifunctional compounds formed by conjugating an EGFR inhibitor moiety to an E3 ligase ligand moiety, the function of which is to recruit a target protein to an E3 ubiquitin ligase for degradation, as well as methods for preparing and using the same. Background Art
[0002] Proteolysis targeting chimeras (PROTACs) consist of two covalently linked protein binding molecules: one molecule is able to engage the E3 ubiquitin ligase, while the other molecule binds to the target protein (POI), i.e., the target for degradation (Sakamoto KM et al., Proc. Natl. Acad. Sci. 2001, 98: 8554-9.; Sakamoto KM et al., Methods Enzymol. 2005; 399: 833-847.). Recruiting the E3 ligase to a specific unwanted protein instead of inhibiting the enzymatic activity of the target protein leads to ubiquitination of the target protein and subsequent degradation of the target protein by the proteasome. The whole process of ubiquitination and proteasomal degradation is called the ubiquitin-proteasome pathway (UPP) (Ardley H. et al., Essays Biochem. 2005, 41, 15-30; Komander D. et al., Biochem. 2012, 81, 203-229; Grice GL et al., Cell Rep. 2015, 12, 545-553; Swatek KN et al., Cell Res. 2016, 26, 399-422). The proteasome is a protein complex that degrades unwanted, misfolded or abnormal proteins into small peptides to maintain the health and productivity of cells. Ubiquitin ligases (also called E3 ubiquitin ligases) directly catalyze the transfer of ubiquitin from E2 to target proteins for degradation. Although the human genome encodes more than 600 putative E3 ligases, only a limited number of E3 ubiquitin ligases have been widely used by small molecule PROTAC technology: cereblon (CRBN), Von Hippel-Lindau (VHL), mouse double minute 2 homolog (MDM2) and cell inhibitor of apoptosis protein (cIAP) (Philipp O. et al., Chem. Biol. 2017, 12, 2570-2578), recombinant human RING finger protein 114 (RNF114) (Spradlin, JN et al., Nat. Chem. Biol. 2019, 15, 747-755) and DDB1 and CUL4-associated factor 16 (DCAF16) (Zhang, X. et al., Nat. Chem. Biol. 2019, 15, 737-746). For example, cereblon (CRBN) forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and Cullin-4A (CUL4A) to ubiquitinate many other proteins, which are then degraded via the proteasome (Yi-An Chen et al., Scientific Reports 2015, 5, 1-13).Immunomodulatory drugs (IMiDs), including thalidomide, lenalidomide, and pomalidomide, work by binding to CRL4A. CRBNThe cereblon (CRBN) subunit of the E3 ligase complex binds and recruits new substrate proteins to act as a monovalent promoter of PPI. (Matyskiela, ME et al., Nat Chem Biol 2018, 14, 981-987). Therefore, the ability of thalidomide and its derivatives to recruit CRBN has been widely used in protein hydrolysis targeting chimeras (PROTAC) related studies (Christopher T. et al. ACS Chem. Biol. 2019, 14, 342-347.; Honorine L. et al., ACS Cent. Sci. 2016, 2, 927-934). PROTAC has great potential to eliminate the "undruggable" protein targets of traditional inhibitors or as non-enzyme proteins. (Chu TT. et al., Cell Chem Biol. 2016; 23: 453-461. Qin C. et al., J Med Chem 2018; 61: 6685-6704. Winter GE. et al., Science 2015; 348: 1376-1381). In recent years, PROTAC has been reported as a useful regulator in anti-tumor research to promote the selective degradation of multiple target proteins.(Lu J. et al., ChemBiol. 2015; 22(6):755-763; Ottis P. et al., Chem Biol. 2017; 12(4):892-898.; Crews CM et al., J Med Chem. 2018; 61(2):403-404; Neklesa TK et al., Pharmacol Ther. 2017, 174:138-144.; Cermakova K. et al., Molecules, 2018. 23(8).; An S. et al., EBioMedicine, 2018.; Lebraud H. et al., Essays Biochem. 2017; 61(5):517-527.; Sun YH et al., Cell Res. 2018; 28:779–81; Toure M. et al., Angew Chem Int Ed Engl.2016;55(6):1966-1973; Yonghui Sun et al., Leukemia, Vol. 33, pp. 2105-2110 (2019); Shaodong Liu et al., Medicinal Chemistry Research, Vol. 29, pp. 802-808 (2020); and has been in patent publications, such as US20160045607, US20170008904, US20180050021, US20180072711, WO2002020740, WO2014108452, WO2016146985, WO2016149668, WO2016197032, WO2016197114, WO201701159 0, WO2017030814, WO2017079267, WO2017182418, WO2017197036, WO2017197046, WO2017197051, WO2017197056, WO2017201449, WO2018071606, WO2021178920, WO2021127283, WO2021127190, WO202111871 and WO202111913.
[0003] The epidermal growth factor receptor (EGFR) belonging to the ErbB family is a transmembrane receptor tyrosine kinase (RTK) that plays a fundamental and key role in cell proliferation, differentiation and motility (Y. Yarden et al., Nat. Rev. Mol. Cell Biol. 2001; 2: 127-137.). Homodimerization or heterodimerization of EGFR and other ErbB family members activates the cytoplasmic tyrosine kinase domain to initiate intracellular signal transduction. Overexpression or activating mutations of EGFR are associated with the development of many types of cancers, such as pancreatic cancer, breast cancer, glioblastoma multiforme, head and neck cancer, and non-small cell lung cancer (Yewale C. et al., Biomaterials. 2013, 34 (34): 8690-8707.). Activating mutations in the EGFR tyrosine kinase domain (L858R mutation and exon 19 deletion) have been identified as oncogenic drivers of NSCLC (Konduri, K. et al., Cancer Discovery 2016, 6 (6), 601-611.). The first generation of EGFR tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib have been approved for use in NSCLC patients with EGFR activating mutations (M. Maemondo, N. Engl. J. Med. 362 (2010) 2380-2388.). Although most patients with EGFR mutant NSCLC respond to these treatments, patients usually develop resistance after an average of one year of treatment. There are several mechanisms of acquired resistance to gefitinib and erlotinib, including secondary threonine 790 to methionine 790 mutation (T790M), also known as the "gatekeeper" T790M mutation (Xu Y. et al., Cancer Biol Ther. 2010, 9 (8): 572-582.). Therefore, the second-generation EGFR-TKI afatinib and the third-generation EGFR-TKI osimertinib (AZD9291) were developed as irreversible EGFR inhibitors combined with Cys797 for the treatment of patients with T790M mutations. In particular, in NSCLC patients with EGFR T790M, osimertinib, which does not substantially target WT EGFR, has achieved higher clinical response rates. However, several recent studies have reported tertiary Cys797 to Ser797 (C797S) point mutations accompanying osimertinib clinical treatment (Thress KS et al., Nat. Med. 2015, 21(6):560-562.) Drugs that can overcome the EGFR (C797S) resistance barrier in non-small cell lung cancer (NSCLC) are needed.EGFR targeting PROTACs are used as a potential strategy to overcome drug resistance mediated by these mutants, which have been disclosed or discussed in patent publications such as WO2018119441, WO2019149922, WO2019183523, WO2019121562, US20190106417, WO202157882, WO2021123087, WO2021133809, WO2021168074, WO2021208918, and WO2021216440.
[0004] Nevertheless, many EGFR-targeted PROTACs designed to degrade EGFR mutant proteins have been disclosed (Zhang X. et al., Eur. J. Med. Chem. 2020, 192, 112199.; Zhang H et al., Eur. J. Med. Chem. 2020, 189, 112061.; Lu X, Med. Res. Rev. 2018, 38 (5): 1550-1581. He K. et al., Bioorg. Med. Chem. Lett. 2020, 15, 127167.). Most of the published molecules are based on first, second and third generation EGFR inhibitors (WO2021023233, WO2019121562 and WO2018119441) or allosteric EGFR inhibitors (WO2021127561). However, there is no data showing that those EGFR-targeting PROTACs degrade all major EGFR mutations, such as Del19, L858R, Del19 / T790M, L858R / T790M, Del19 / T790M / C797S, and L858R / T790M / C797S.
[0005] The present application provides novel bifunctional compounds, intermediates and methods for treating serious diseases. Summary of the invention
[0006] One object of the present invention is to provide compounds and derivatives formed by conjugating an EGFR inhibitor moiety with an E3 ligase ligand moiety, the function of which is to recruit target proteins to E3 ubiquitin ligases for degradation, as well as preparation methods and uses thereof.
[0007] The compounds described herein or their salts can be used to treat diseases that may be affected by EGFR regulation. The present invention provides the use of the compounds described herein or their pharmaceutically acceptable salts for the manufacture of medicaments for treating diseases that may be affected by EGFR regulation. The present invention further provides compounds described herein or their pharmaceutically acceptable salts for the treatment of diseases that may be affected by EGFR regulation. The present application further provides a method for treating a proliferative disorder, the method comprising administering a therapeutically effective amount of a compound described herein or its pharmaceutically acceptable salt to a subject in need thereof.
[0008] In one embodiment, the bifunctional compound is of formula (X):
[0009]
[0010] or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a tautomer thereof, or a deuterated analog thereof, or a prodrug thereof,
[0011] in:
[0012] E 1 N or CR 5 ;
[0013] E 2 N or CR 6 ;
[0014] R 1a , R 1b , R 2a and R 2b are each independently absent, hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy, -C 3-8 Cycloalkyl or -CN; each of the -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy or -C 3-8 Cycloalkyl is optionally selected from hydrogen, halogen, -C 1-8 Alkoxy, -C 3-8 substituted with at least one substituent of cycloalkyl or -CN;
[0015] R 3 and R 4 are independently hydrogen, -C 1-6 Alkyl or -C 3-8 Cycloalkyl; each of the -C 1-6 Alkyl or -C 3-8Cycloalkyl is optionally selected from hydrogen, halogen, -C 1-6 The alkoxy group is substituted with at least one substituent;
[0016] R 5 and R 6 are each independently absent, hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy, -C 3-8 Cycloalkyl or -CN; each of the -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy or -C 3-8 Cycloalkyl is optionally selected from hydrogen, halogen, -C 1-8 Alkoxy, -C 3-8 cycloalkyl or -CN is substituted with at least one substituent; or
[0017] R 5 and R 6 Together with the carbon atom to which it is attached, it forms a 3- to 12-membered ring, the ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent halogen, hydroxyl or -C1-C8 alkyl;
[0018] R 7 are each independently absent, hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy, -C 3-8 Cycloalkyl or -CN; each of the -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy or -C 3-8 Cycloalkyl is optionally selected from hydrogen, halogen, -C 1-8 Alkoxy, -C 3-8 cycloalkyl or -CN is substituted with at least one substituent; or
[0019] Two R's 7 Together with the carbon atom to which it is attached, it forms a 3- to 12-membered ring, the ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent halogen, hydroxyl or -C1-C8 alkyl;
[0020] R 8 and R 9Each is independently selected from hydrogen, halogen, -C1-C6 alkyl or C3-C8 cycloalkyl; -C1-C6 alkyl or C3-C8 cycloalkyl are each optionally selected from hydrogen, halogen, hydroxyl, -C 1-6 The alkoxy group is substituted with at least one substituent;
[0021] R 10 Each is independently selected from hydrogen, halogen, -C1-C8 alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Aryl, 5- to 12-membered heteroaryl, -NR 10a R 10b 、-OR 10a 、-SR 10a 、-C(O)R 10a 、-CO2R 10a 、-C(O)NR 10a R 10b 、-NR 10a COR 10b 、-NR 10a CO2R 10b or -NR 10a S02R 10b or -CN; -C1-C8 alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 The aryl or 5- to 12-membered heteroaryl groups are each optionally substituted with at least one R 10c replace;
[0022] R 10a and R 10b Each is independently selected from hydrogen, -C1-C8 alkyl, -C2-C8 alkenyl, -C2-C8 alkynyl, C3-C8 cycloalkyl, 3 to 8 membered heterocyclyl, C6-C 12 aryl or 5 to 12 membered heteroaryl, each of the -C1-C8 alkyl, -C2-C8 alkenyl, -C2-C8 alkynyl, C3-C8 cycloalkyl, 3 to 8 membered heterocyclyl, C6-C 12 The aryl or 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R 10d replace;
[0023] R 10c and R 10d Each is independently selected from halogen, hydrogen, -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, C3-C8 cycloalkyl, 3 to 8 membered heterocyclyl, C6-C 12 aryl, 5- to 12-membered heteroaryl, oxo (=O), -NR10e R 10f 、-OR 10e 、-SR 10e 、-SO2R 10e 、-SO2NR 10e R 10f 、-C(O)R 10e 、-CO2R 10e 、-C(O)NR 10e R 10f 、-NR 10e COR 10f 、-NR 10e CO2R 8f or -NR 10e S02R 10f or -CN;
[0024] R 10e and R 10f Each is independently selected from hydrogen, -C1-C8 alkyl, -C2-C8 alkenyl, -C2-C8 alkynyl, C3-C8 cycloalkyl, 3 to 8 membered heterocyclyl, C6-C 12 Aryl or 5- to 12-membered heteroaryl;
[0025] R 11a , R 11b , R 11c , R 11d , R 12a , R 12b , R 12c and R 12d are each independently absent, oxo, hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy or -C 3-8 Cycloalkyl; the -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy or -C 3-8 The cycloalkyl groups are each optionally selected from hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 is substituted with at least one substituent of alkoxy or -CN;
[0026] L 1 Independently selected from -O-, -NR a -、-C(O)-、* L1 -C(O)NR a -** L1,* L1 -C(O)O-** L1 ,* L1 -NR a C(O)-** L1 ,* L1 -OC(O)-** L1 ,
[0027] It is stated
[0028] Each is optionally represented by at least one R L1c replace;
[0029] in* L1 refers to Partially connected locations, and ** L1 refers to Location of partial connections;
[0030] L 2 Independently selected from -O-, -NR a -、-C(O)-、* L2 -C(O)NR a -** L2 ,* L2 -C(O)O-** L2 ,* L2 -NR a C(O)-** L2 ,* L2 -OC(O)-** L2 ,
[0031] It is stated Each is optionally represented by at least one R L2c replace;
[0032] in* L2 refers to Partially connected locations, and ** L2 refers to Location of partial connections;
[0033] L 3 Independently selected from -O-, -NR a -、-C(O)-、* L3 -C(O)NR a -** L3 ,*L3 -C(O)O-** L3 ,* L3 -NR a C(O)-** L3 ,* L3 -OC(O)-** L3 , It is stated Each is optionally represented by at least one R L3c replace;
[0034] in* L3 refers to Partially connected locations, and ** L3 refers to Location of partial connections;
[0035] The R L1c , R L2c and R L3c Each is independently absent, oxo (=O), halogen, hydroxy, -CN, -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl, C6-C 12 aryl or 5 to 12 membered heteroaryl; the -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, C3-C8 cycloalkyl, 3 to 8 membered heterocyclyl, C6-C 12 The aryl and 5- to 12-membered heteroaryl groups are each optionally substituted with at least one R Lca replace,
[0036] R Lca are independently absent, oxo (=O), halogen, hydroxy, -CN, -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl, C6-C 12 Aryl or 5- to 12-membered heteroaryl; or
[0037] Two R's L1c Together with the atoms to which it is attached, it forms a 3- to 12-membered ring, the ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent halogen, hydroxyl, -C1-C8 alkyl;
[0038] Two R's L2cTogether with the atoms to which it is attached, it forms a 3- to 12-membered ring, the ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent halogen, hydroxyl, -C1-C8 alkyl;
[0039] Two R's L3c Together with the atoms to which it is attached, it forms a 3- to 12-membered ring, the ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent halogen, hydroxyl, -C1-C8 alkyl;
[0040] Selected from
[0041] Z 1 ,Z 2 and Z 3 Each independently is N or CR z , the condition is that Z 1 , Z 2 and Z 3 Not all are N;
[0042] R z is independently selected at each occurrence from absence, hydrogen, halogen, -C 1-8 Alkyl, -NR Za R Zb 、-OR Za 、-SR Za , C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl or CN; -C 1-8 The alkyl group, C3-C8 cycloalkyl group, and 3- to 8-membered heterocyclic group are each optionally substituted by at least one R Zc replace;
[0043] Partially through Z 1 or Z 2 Any one of (which is CR z And R z does not exist) connected to part;
[0044] R Za and R Zb Each is independently selected from the group consisting of absent, hydrogen, -C1-C8 alkyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl, C6-C 12 aryl or 5 to 12 membered heteroaryl, each of the -C 1-8 Alkyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 The aryl or 5- to 12-membered heteroaryl group is optionally substituted by at least one substituent R Zd replace;
[0045] RZc and R Zd are independently halogen, hydroxy, -C1-C8 alkyl, -C 1-8 Alkoxy, C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Aryl or 5- to 12-membered heteroaryl;
[0046] R 13 and R 14 are each independently selected from the group consisting of absence, hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy, -C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, -C6-C 12 Aryl, 5- to 12-membered heteroaryl, -CN, -SO2R 13a 、-SO2NR 13a R 13b 、-COR 13a ,-CO2R 13a 、-CONR 13a R 13b 、-NR 13a R 13b 、-NR 13a COR 13b 、-NR 13a CO2R 13b or –NR 13a S02R 13b ;-C 1-8 Alkyl-C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy, -C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, -C6-C 12 The aryl or 5- to 12-membered heteroaryl groups are each optionally substituted by halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Aryl, 5- to 12-membered heteroaryl, oxo, -CN, -OR 13c 、-SO2R 13c 、-SO2NR 13c R 13d 、-COR 13c 、-CO2R 13c 、-CONR 13c R 13d 、-NR 13c R 13d 、-NR 13c COR13d 、-NR 13c CO2R 13d or –NR 13c S02R 13d ;
[0047] At each occurrence, R 13a , R 13b , R 13c and R 13d are each independently absent, hydrogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclic group, C6-C 12 Aryl or 5- to 12-membered heteroaryl;
[0048] L 4 , L 5 and L 6 are each independently selected from absence, a single bond, -O-, -NR a -、-(CR a R b ) n8 -、-O(CR a R b ) n8 -、-NR a (CR a R b ) n8 -or-C(O)-;
[0049] At each occurrence, X 1 , X 2 and X 7 Each independently selected from -CR a or N;
[0050] At each occurrence, X 3 , X 4 and X 8 Each independently selected from -NR a -, -O-, -S-, and -CR a R b -;
[0051] At each occurrence, X 5 and X 6 are each independently selected from the group consisting of absence, a single bond, -C(O)-, -NR a - and -O-;
[0052] At each occurrence, R a and R bEach is independently selected from hydrogen, hydroxy, halogen, CN, -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, -C3-C8 cycloalkyl, 3 to 8 membered heterocyclyl, -C6-C 12 The -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, -C3-C8 cycloalkyl, 3- to 8-membered heterocyclic, -C6-C 12 The aryl or 5 to 12 membered heteroaryl groups are each optionally substituted with at least one substituted group halogen, hydroxyl, halogen, -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, -C3-C8 cycloalkyl, 3 to 8 membered heterocyclyl, -C6-C8 cycloalkyl, -C8-C8 cycloalkyl ... 12 aryl or 5- to 12-membered heteroaryl; or
[0053] R a and R b The carbon atom to which it is attached forms a 3- to 12-membered ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituted halogen, hydroxyl, -C1-C8 alkyl, -C2-C8 alkenyl, -C2-C8 alkynyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl, C6-C 12 aryl or 5- to 12-membered heteroaryl substituted;
[0054] m1, m2, m3 and m4 are each independently 0, 1 or 2; provided that m1+m2+m3+m4≤4;
[0055] m5, m6 and m7 are each independently 0, 1 or 2; provided that m5+m6+m7≥1;
[0056] n1, n2, n3, n4 and n5 are each independently 0, 1, 2 or 3;
[0057] n6 are each independently 0, 1, 2, 3 or 4;
[0058] n7 and n8 are each independently 0, 1, 2 or 3;
[0059] s1 and s2 are each independently 0, 1, 2 or 3;
[0060] s5, s6 and s7 are each independently 0, 1, 2 or 3;
[0061] The condition is
[0062] For L 1 , L 2 or L 3 Any one of them, when X1 When N, X 5 is a single bond, absent, -C(O)-; and / or when X 2 When N, X 6 is a single bond, absent, -C(O)-;
[0063] When L 1 for When X 1 When N, X 5 is a single bond, absent, -C(O)-; and / or X 3 For –CR a R b -; When X 2 When N, X 6 is a single bond, absent, -C(O)-, and / or X 4 For –CR a R b -;
[0064] When L 2 for When X 1 When N, X 5 is a single bond, absent, -C(O)-; and / or X 3 For –CR a R b -; When X 2 When N, X 6 is a single bond, absent, -C(O)-, and / or X 4 For –CR a R b -;
[0065] When L 3 for When X 1 When N, X 5 is a single bond, absent, -C(O)-; and / or X 3 For –CR a R b -; When X 2 When N, X 6 is a single bond, absent, -C(O)-, and / or X 4 For –CR a R b -.
[0066] Another object of the present invention is to provide intermediates and methods of compound (X), which is formed by conjugating an EGFR inhibitor portion with an E3 ligase ligand portion, the function of which is to recruit the target protein to the E3 ubiquitin ligase for degradation, as well as preparation methods and uses thereof.
[0067] Aspect 1. A compound of formula (I):
[0068]
[0069] or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a tautomer thereof, or a deuterated analog thereof, or a prodrug thereof,
[0070] in:
[0071] R 1a , R 1b , R 2a and R 2b are each independently absent, hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy, -C 3-8 Cycloalkyl or -CN; each of the -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy or -C 3-8 Cycloalkyl is optionally selected from hydrogen, halogen, -C 1-8 Alkoxy, -C 3-8 substituted with at least one substituent of cycloalkyl or -CN;
[0072] R 3 and R 4 are independently hydrogen, -C 1-6 Alkyl or -C 3-8 Cycloalkyl; each of the -C 1-6 Alkyl or -C 3-8 Cycloalkyl is optionally selected from hydrogen, halogen, -C 1-6 The alkoxy group is substituted with at least one substituent;
[0073] R 7 are each independently absent, hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy, -C 3-8 Cycloalkyl or -CN; each of the -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy or -C 3-8 Cycloalkyl is optionally selected from hydrogen, halogen, -C 1-8 Alkoxy, -C 3-8 cycloalkyl or -CN is substituted with at least one substituent; or
[0074] Two R's 7 Together with the carbon atom to which it is attached, it forms a 3- to 12-membered ring, the ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent halogen, hydroxyl or -C1-C8 alkyl;
[0075] R 8 and R 9 Each is independently selected from hydrogen, halogen, -C1-C6 alkyl or C3-C8 cycloalkyl; -C1-C6 alkyl or C3-C8 cycloalkyl are each optionally selected from hydrogen, halogen, -C 1-6 The alkoxy group is substituted with at least one substituent;
[0076] R 10 Each independently selected from halogen, It is stated
[0077] Each is optionally represented by at least one R 10a replace;
[0078] The R 10a Each is independently absent, oxo (=O), halogen, hydroxy, -CN, -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl, C6-C 12 aryl or 5 to 12 membered heteroaryl; the -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, C3-C8 cycloalkyl, 3 to 8 membered heterocyclyl, C6-C 12 The aryl and 5- to 12-membered heteroaryl groups are each optionally substituted with at least one R 10b replace,
[0079] R 10b are independently absent, oxo (=O), halogen, hydroxy, -CN, -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl, C6-C 12 Aryl or 5- to 12-membered heteroaryl; or
[0080] Two R's 10a Together with the atoms to which it is attached, it forms a 3- to 12-membered ring, the ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent halogen, hydroxyl, -C1-C8 alkyl;
[0081] At each occurrence, X1 Each independently selected from -CR a or N;
[0082] At each occurrence, X 2 are each independently selected from -NH- or -C(O)-;
[0083] At each occurrence, X 3 Each independently selected from -NR a -, -O-, -S-, and -CR a R b -;
[0084] At each occurrence, R a and R b Each is independently selected from hydrogen, hydroxy, halogen, CN, -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, -C3-C8 cycloalkyl, 3 to 8 membered heterocyclyl, -C6-C 12 The -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, -C3-C8 cycloalkyl, 3- to 8-membered heterocyclic, -C6-C 12 The aryl or 5 to 12 membered heteroaryl groups are each optionally substituted with at least one substituted group halogen, hydroxyl, halogen, -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, -C3-C8 cycloalkyl, 3 to 8 membered heterocyclyl, -C6-C8 cycloalkyl, -C8-C8 cycloalkyl ... 12 aryl or 5- to 12-membered heteroaryl; or
[0085] R a and R b The carbon atom to which it is attached forms a 3- to 12-membered ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituted halogen, hydroxyl, -C1-C8 alkyl, -C2-C8 alkenyl, -C2-C8 alkynyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl, C6-C 12 aryl or 5- to 12-membered heteroaryl substituted;
[0086] n1, n2, n3, n4 and n5 are each independently 0, 1, 2 or 3;
[0087] s5, s6 and s7 are each independently 0, 1, 2 or 3.
[0088] Aspect 2. The compound according to aspect 1, wherein the compound is selected from formula (IIa),
[0089]
[0090] Preferably, the compound is selected from formula (IIb) and (IIc):
[0091]
[0092] Preferably, the compound is selected from formula (IId) and (IIe):
[0093]
[0094] Preferably, the compound is selected from formula (IIf) and (Ig):
[0095]
[0096] Where R 3 , R 4 , R 7 , R 8 , R 9 , R 10 , s5, s6 and s7 are as defined in aspect 1.
[0097] Aspect 3. A compound according to any one of the preceding aspects, wherein R 1a , R 1b , R 2a and R 2b are each independently hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 alkynyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or -CN; wherein each of the methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl are optionally substituted with at least one substituent selected from hydrogen, F, Cl, Br, I, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or -CN;
[0098] Preferably, R 1a , R 1b , R 2a and R 2beach independently represents hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -CF3, -CHF2, -CN, -CH2OCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH2CH2OCH2CH3;
[0099] More preferably, R 1a , R 1b , R 2a and R 2b Each is independently hydrogen, F, Cl, methyl, methoxy, cyclopropyl, -CF3 or -CHF2, -CH2OCH3;
[0100] More preferably, R 1a , R 1b , R 2a and R 2b are each independently hydrogen.
[0101] Aspect 4. A compound according to any one of the preceding aspects, wherein R 3 and R 4 are each independently hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; the methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl being optionally substituted with at least one substituent selected from hydrogen, F, Cl, Br, I, methoxy, ethoxy, propoxy, butoxy, pentyloxy or hexyloxy;
[0102] Preferably, R 3 and R 4 are each independently hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; preferably, R 3 are independently methyl, and R 4 For hydrogen.
[0103] Aspect 5. A compound according to any one of the preceding aspects, wherein R 7 each independently represents hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -CF3, -CHF2, -CN, -CH2OCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH2CH2OCH2CH3;
[0104] Preferably, R 7 Each is independently hydrogen, F, Cl, methyl, methoxy, cyclopropyl, -CF3 or -CHF2, -CH2OCH3.
[0105] Aspect 6. A compound according to any one of the preceding aspects, wherein two R 7 The carbon atom to which it is attached forms a 3-, 4-, 5-, 6-, 7- or 8-membered ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent F, Cl, Br, I, hydroxyl, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl or octyl;
[0106] Preferably, the two R 7 The carbon atom to which it is attached forms a 3-, 4-, 5- or 6-membered ring, which is optionally substituted with at least one substituent F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl or octyl.
[0107] Aspect 7. A compound according to any one of the preceding aspects, wherein R 8 and R 9 Each is independently selected from hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; the methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl is optionally substituted with at least one substituent selected from hydrogen, F, Cl, Br, I, methoxy, ethoxy, propoxy, butoxy, pentyloxy or hexyloxy;
[0108] Preferably, R 8 and R 9 are each independently hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; preferably, R 8 are independently hydrogen, and R 9 is F or methyl.
[0109] Aspect 8. A compound according to any one of the preceding aspects, wherein R 10 Each independently selected from hydrogen, -F, -Cl, -Br, -I,
[0110] It is stated
[0111] Each is optionally represented by at least one R 10a replace;
[0112] The R 10a R is each independently hydrogen, oxo (=O), F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, heptyl, octyl, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3-8 membered heterocyclyl, phenyl, or 5-12 membered heteroaryl; the methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, heptyl, octyl, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3-8 membered heterocyclyl, phenyl, and 5-12 membered heteroaryl are each optionally substituted by at least one R 10b replace,
[0113] R 10b are independently oxo (═O), F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; or
[0114] Two R's 10a Together with the carbon atoms to which they are attached, they form a 3, 4, 5, 6, 7 or 8 membered ring comprising 0, 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl or octyl;
[0115] Preferably, R 10 Each independently selected from hydrogen, -F, -Cl, -Br, -I,
[0116]
[0117]
[0118] Aspect 9. A compound according to any one of the preceding aspects, selected from
[0119]
[0120] Another object of the present invention is to provide intermediates and methods of compound (X), which is formed by conjugating an EGFR inhibitor portion with an E3 ligase ligand portion, the function of which is to recruit the target protein to the E3 ubiquitin ligase for degradation, as well as preparation methods and uses thereof. DETAILED DESCRIPTION
[0121] The following terms have the indicated meanings throughout the specification:
[0122] Unless specifically defined elsewhere in this document, all other technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0123] The following terms have the indicated meanings throughout the specification:
[0124] As used herein, including the appended claims, singular forms of words such as "a," "an," and "the" include their corresponding plural referents unless the context clearly dictates otherwise.
[0125] Unless the context clearly dictates otherwise, the term "or" is used to mean, and is used interchangeably with, the term "and / or."
[0126] The term "alkyl" includes hydrocarbon groups selected from straight and branched chain saturated hydrocarbon groups containing 1 to 18 (such as 1 to 12, further such as 1 to 10, further such as 1 to 8, or 1 to 6, or 1 to 4) carbon atoms. 1-6 Examples of alkyl) include, but are not limited to, methyl, ethyl, 1-propyl or n-propyl ("n-Pr"), 2-propyl or isopropyl ("i-Pr"), 1-butyl or n-butyl ("n-Bu"), 2-methyl-1-propyl or isobutyl ("i-Bu"), 1-methylpropyl or sec-butyl ("s-Bu"), 1,1-dimethylethyl or tert-butyl ("t-Bu"), 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, and 3,3-dimethyl-2-butyl.
[0127] The term "propyl" includes 1-propyl or n-propyl ("n-Pr"), 2-propyl or isopropyl ("i-Pr").
[0128] The term "butyl" includes 1-butyl or n-butyl ("n-Bu"), 2-methyl-1-propyl or isobutyl ("i-Bu"), 1-methylpropyl or sec-butyl ("s-Bu"), 1,1-dimethylethyl or tert-butyl ("t-Bu").
[0129] The term "pentyl" includes 1-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl.
[0130] The term "hexyl" includes 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl and 3,3-dimethyl-2-butyl.
[0131] The term "alkylene" refers to a divalent alkyl group produced by removing two hydrogens from an alkane. Alkylene includes, but is not limited to, methylene, ethylene, propylene, and the like.
[0132] The term "halogen" includes fluorine (F), chlorine (Cl), bromine (Br) and iodine (I).
[0133] The term "alkenyl" includes hydrocarbon groups selected from straight and branched hydrocarbon groups containing at least one C=C double bond and 2 to 18 (such as 2 to 8, further such as 2 to 6) carbon atoms. 2-6 Examples of alkenyl groups include, but are not limited to, ethenyl or vinyl, prop-1-enyl, prop-2-enyl, 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, buta-1,3-dienyl, 2-methylbuta-1,3-dienyl, hex-1-enyl, hex-2-enyl, hex-3-enyl, hex-4-enyl, and hex-1,3-dienyl.
[0134] The term "alkenylene" refers to a divalent alkenyl group generated by removing two hydrogens from an alkene. Alkenylene includes, but is not limited to, vinylene, butenylene, and the like.
[0135] The term "alkynyl" includes hydrocarbon groups selected from straight and branched hydrocarbon groups containing at least one C≡C triple bond and 2 to 18 (such as 2 to 8, further such as 2 to 6) carbon atoms. 2-6 Examples of alkynyl groups include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl (propargyl), 1-butynyl, 2-butynyl, and 3-butynyl.
[0136] The term "alkynylene" refers to a divalent alkynyl group generated by removing two hydrogen atoms from an alkyne. Alkynylenes include, but are not limited to, ethynylene and the like.
[0137] The term "cycloalkyl" includes hydrocarbon groups selected from saturated cyclic hydrocarbon groups, including monocyclic and polycyclic (eg, bicyclic and tricyclic) groups, including fused, bridged or spiro-connected cycloalkyl groups.
[0138] For example, cycloalkyl can contain 3 to 12 (such as 3 to 10, further such as 3 to 8, further such as 3 to 6, 3 to 5 or 3 to 4) carbon atoms. Even further for example, cycloalkyl can be selected from the monocyclic group containing 3 to 12 (such as 3 to 10, further such as 3 to 8, 3 to 6) carbon atoms. The example of monocyclic cycloalkyl includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl and cyclododecyl. In particular, saturated monocyclic cycloalkyl (for example, C 3-8 Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. In a preferred embodiment, a cycloalkyl group is a monocyclic ring (abbreviated as C 3-6 Examples of bicyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Examples of bicyclic cycloalkyls include those with 7 to 12 ring atoms, arranged as fused bicyclics selected from [4,4], [4,5], [5,5], [5,6] and [6,6] ring systems, or arranged as bridged bicyclics selected from bicyclic [2.2.1] heptane, bicyclic [2.2.2] octane and bicyclic [3.2.2] nonane. Other examples of bicyclic cycloalkyls include those arranged as bicyclics selected from [5,6] and [6,6] ring systems.
[0139] The term "spirocycloalkyl" includes cyclic structures containing carbon atoms and formed by at least two rings that share one atom.
[0140] The term "fused cycloalkyl" includes bicyclic cycloalkyls as defined herein which are saturated and formed by two or more rings sharing two adjacent atoms.
[0141] The term "bridged cycloalkyl" includes a cyclic structure containing carbon atoms and formed by two rings, and the two rings share two atoms that are not adjacent to each other. The term "7-10 membered bridged cycloalkyl" includes a cyclic structure containing 7 to 12 carbon atoms and formed by two rings, and the two rings share two atoms that are not adjacent to each other.
[0142] Examples of fused cycloalkyl, fused cycloalkenyl or fused cycloalkynyl groups include, but are not limited to, bicyclo[1.1.0]butyl, bicyclo[2.1.0]pentyl, bicyclo[3.1.0]hexyl, bicyclo[4.1.0]heptyl, bicyclo[3.3.0]octyl, bicyclo[4.2.0]octyl, decalin, and benzo 3 to 8 membered cycloalkyl, benzo C 4-6Cycloalkenyl, 2,3-dihydro-1H-indenyl, 1H-indenyl, 1,2,3,4-tetrahydronaphthyl, 1,4-dihydronaphthyl, etc. A preferred embodiment is an 8- to 9-membered fused ring, which in the above examples refers to a cyclic structure containing 8 to 9 ring atoms.
[0143] The term "aryl" used alone or in combination with other terms includes groups selected from:
[0144] 5- and 6-membered carbocyclic aromatic rings, e.g., phenyl;
[0145] Bicyclic ring systems, such as 7- to 12-membered bicyclic ring systems in which at least one ring is carbocyclic and aromatic, for example, naphthyl and indanyl; and
[0146] A tricyclic ring system, such as a 10- to 15-membered tricyclic ring system, wherein at least one ring is carbocyclic and aromatic, for example, fluorenyl.
[0147] The terms "aromatic hydrocarbon ring" and "aryl" are used interchangeably throughout the disclosure herein. In some embodiments, the monocyclic or bicyclic aromatic hydrocarbon ring has 5 to 10 ring carbon atoms (i.e., C 5-10 Examples of monocyclic or bicyclic aromatic hydrocarbon rings include, but are not limited to, phenyl, naphthalene-1-yl, naphthalene-2-yl, anthracenyl, phenanthrenyl, etc. In some embodiments, the aromatic hydrocarbon ring is a naphthalene ring (naphthalene-1-yl or naphthalene-2-yl) or a phenyl ring. In some embodiments, the aromatic hydrocarbon ring is a phenyl ring.
[0148] Specifically, the term "bicyclic fused aryl" embraces bicyclic aryl rings as defined herein. A typical bicyclic fused aryl is naphthalene.
[0149] The term "heteroaryl" includes groups selected from:
[0150] A 5-, 6-, or 7-membered aromatic monocyclic ring comprising at least one heteroatom selected from nitrogen (N), sulfur (S), and oxygen (O), for example, 1 to 4 (or in some embodiments, 1 to 3, in some embodiments, 1 to 2) heteroatoms, the remaining ring atoms being carbon;
[0151] 7- to 12-membered bicyclic rings comprising at least one heteroatom selected from N, O and S, e.g., 1 to 4 (or in some embodiments, 1 to 3, or in other embodiments, 1 or 2) heteroatoms, the remaining ring atoms being carbon, and wherein at least one ring is aromatic and at least one heteroatom is present in an aromatic ring; and
[0152] An 11- to 14-membered tricyclic ring comprising at least one heteroatom selected from N, O and S, e.g., 1 to 4 (or in some embodiments, 1 to 3, or in other embodiments, 1 or 2) heteroatoms, the remaining ring atoms being carbon, and wherein at least one ring is aromatic and at least one heteroatom is present in an aromatic ring.
[0153] When the total number of S and O atoms in the heteroaryl group exceeds 1, those heteroatoms are not adjacent to each other. In some embodiments, the total number of S and O atoms in the heteroaryl group does not exceed 2. In some embodiments, the total number of S and O atoms in the aromatic heterocycle does not exceed 1. When the heteroaryl group contains more than one heteroatom ring member, the heteroatoms can be the same or different. The nitrogen atoms in one or more rings of the heteroaryl group can be oxidized to form N-oxides.
[0154] Specifically, the term "bicyclic fused heteroaryl" includes 7 to 12 members, preferably 7 to 10 members, more preferably 9 or 10 members, of fused bicyclic heteroaryl rings as defined herein. Typically, the bicyclic fused heteroaryl is a 5 / 5-membered, 5 / 6-membered, 6 / 6-membered or 6 / 7-membered bicyclic ring. The group may be attached to the rest of the molecule via either ring.
[0155] "Heterocyclyl", "heterocycle" or "heterocyclic" are interchangeable and include non-aromatic heterocyclic groups containing one or more heteroatoms selected from nitrogen, oxygen or optionally oxidized sulfur as ring members, the remaining ring members being carbon, including monocyclic, fused, bridged and spirocyclic rings, i.e., containing monocyclic heterocyclyls, bridged heterocyclyls, spiro heterocyclyls and fused heterocyclyls.
[0156] The term "H" or "hydrogen" disclosed herein includes hydrogen and the non-radioactive isotope deuterium.
[0157] The term "at least one substituent" disclosed herein includes, for example, 1 to 4 (such as 1 to 3, further such as 1 or 2) substituents, provided that it conforms to the valence theory. For example, "at least one substituent F" disclosed herein includes 1 to 4 (such as 1 to 3, further such as 1 or 2) substituents F.
[0158] The term "divalent" refers to a linking group that is capable of forming a covalent bond with two other moieties. For example, a "divalent cycloalkyl" refers to a cycloalkyl obtained by removing two hydrogens from the corresponding cycloalkane to form a linking group. The terms "divalent aryl", "divalent heterocyclyl" or "divalent heteroaryl" should be understood in a similar manner.
[0159] The compounds disclosed herein may contain asymmetric centers and therefore may exist as enantiomers. "Enantiomers" refer to two stereoisomers of a compound that are non-superimposable mirror images of each other. In the case where the compounds disclosed herein have two or more asymmetric centers, they may additionally exist as diastereomers. Enantiomers and diastereomers belong to a wider class of stereoisomers. It is intended to include all such possible stereoisomers in the form of substantially pure resolved enantiomers, racemic mixtures thereof, and mixtures of diastereomers. It is intended to include all stereoisomers of the compounds disclosed herein and / or their pharmaceutically acceptable salts. Unless otherwise specifically noted, a reference to an isomer is applicable to any possible isomer. As long as the isomer composition is not specified, all possible isomers are included.
[0160] Unless stated otherwise, when compounds disclosed herein contain olefinic double bonds, such double bonds are intended to include both E and Z geometric isomers.
[0161] When the compounds disclosed herein contain a disubstituted cyclic ring system, the substituents found on such ring systems can take cis and trans forms. The cis form means that both substituents are located on the upper side of the 2 substituent positions on the carbon, while the trans form means that they are located on the opposite side. For example, the disubstituted cyclic ring system can be a cyclohexyl ring or a cyclobutyl ring.
[0162] It may be advantageous to separate the reaction products from each other and / or from the starting materials. The desired product of each step or series of steps is separated and / or purified (hereinafter separated) to a desired degree of homogeneity by techniques commonly used in the art. Typically, such separations involve multiphase extraction, crystallization from a solvent or solvent mixture, distillation, sublimation, or chromatography. Chromatography may involve any number of methods, including, for example: reverse phase and normal phase chromatography; size exclusion chromatography; ion exchange chromatography; high pressure, medium pressure, and low pressure liquid chromatography methods and apparatus; small scale analytical chromatography; simulated moving bed ("SMB") chromatography and preparative thin or thick layer chromatography, as well as small scale thin layer and flash chromatography techniques. Those skilled in the art may select and apply the technique most likely to achieve the desired separation.
[0163] "Diastereoisomers" refer to stereoisomers of compounds that have two or more chiral centers but are not mirror images of each other. Diastereomeric mixtures can be separated into their individual diastereomers based on their physicochemical differences by methods well known to those skilled in the art, such as by chromatography and / or fractional crystallization. Enantiomers can be separated by reacting the enantiomeric mixture with an appropriate optically active compound (e.g., a chiral auxiliary, such as a chiral alcohol or Mosher's acid chloride), converting the enantiomer mixture into a diastereomeric mixture, separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers into the corresponding pure enantiomers. Enantiomers can also be separated by using a chiral HPLC column.
[0164] Single stereoisomers (e.g., substantially pure enantiomers) can be obtained by resolving racemic mixtures using a method such as using an optically active resolving agent to form diastereomers (Eliel, E. and Wilen, S. Stereochemistry of Organic Compounds. New York: John Wiley & Sons, Inc., 1994; Lochmuller, CH et al., "Chromatographic resolution of enantiomers: Selective review." J. Chromatogr., 113 (3) (1975): p. 283-302). Racemic mixtures of chiral compounds of the present invention can be separated and isolated by any suitable method, including: (1) forming ionic diastereomeric salts with chiral compounds and separating them by fractional crystallization or other methods, (2) forming diastereomeric compounds with chiral derivatizing agents, separating the diastereomers and converting them to pure stereoisomers, and (3) isolating substantially pure or enriched stereoisomers directly under chiral conditions. See: Wainer, Irving W., ed., Drug Stereochemistry: Analytical Methods and Pharmacology. New York: Marcel Dekker, Inc., 1993.
[0165] Some compounds disclosed herein may exist with different points of hydrogen attachment, known as tautomers. For example, a compound comprising a carbonyl -CH2C(O)- group (keto form) may undergo tautomerism to form a hydroxyl -CH=C(OH)- group (enol form). Where applicable, both the individual keto and enol forms and mixtures thereof are also intended. For another example, a compound comprising a pyrazolyl group may undergo tautomerism to form different rings, as shown below:
[0166]
[0167] As another example, a compound including a guanidine group in the ring may undergo tautomerism to form a different ring, as shown below:
[0168]
[0169] "Prodrug" refers to a derivative of an active agent that requires conversion in vivo to release the active agent. In some embodiments, the conversion is an enzymatic conversion. Prodrugs are usually (but not necessarily) pharmacologically inactive prior to conversion to the active agent.
[0170] "Deuterated analogs" refers to derivatives of an active agent in which any hydrogen is replaced by deuterium. In some embodiments, the deuterated site is located on the warhead portion. In some embodiments, the deuterated site is located on the linker portion. In some embodiments, the deuterated site is located on the degron portion.
[0171] "Pharmaceutically acceptable salts" refers to those salts which are suitable, within the scope of sound medical judgment, for use in contact with the tissues of humans and lower animals without excessive toxicity, irritation, allergic response, and the like, and commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts can be prepared in situ during the final isolation and purification of the compounds disclosed herein, or separately by reacting a free base functional group with a suitable organic acid or by reacting an acidic group with a suitable base. The term also includes salts of stereoisomers (such as enantiomers and / or diastereomers), tautomers, and prodrugs of the compounds of the invention.
[0172] In addition, if the compounds disclosed herein are obtained as acid addition salts, the free base can be obtained by alkalizing a solution of the acid salt. Conversely, if the product is a free base, an addition salt, such as a pharmaceutically acceptable addition salt, can be prepared according to conventional methods for preparing acid addition salts from base compounds by dissolving the free base in a suitable organic solvent and treating the solution with an acid. Those skilled in the art will recognize various synthetic methods that can be used to prepare non-toxic pharmaceutically acceptable addition salts without undue experimentation.
[0173] As used herein, the terms "administration," "administering," "treating," and "treatment" refer to contact of an exogenous drug, therapeutic agent, diagnostic agent, or composition with an animal, human, subject, cell, tissue, organ, or biological fluid. Treatment of cells encompasses contact of an agent with a cell, as well as contact of an agent with a fluid, wherein the fluid is in contact with the cell. The terms "administering" and "treatment" also refer to in vitro and ex vivo treatment of a cell, for example, by an agent, diagnostic agent, binding compound, or by another cell. The term "subject" herein includes any organism, preferably an animal, more preferably a mammal (e.g., rats, mice, dogs, cats, and rabbits), and most preferably a human.
[0174] As used herein, the terms "treated" or "treating" or "treatment" also generally refer to obtaining a desired pharmacological and / or physiological effect. The effect may be prophylactic, in terms of total or partial prevention of a disease or its symptoms; and / or may be therapeutic, in terms of partial or complete stabilization or cure of the disease and / or side effects caused by the disease. As used herein, "treated" or "treating" or "treatment" encompasses any treatment of a disease in a patient, including: (a) prevention of a disease or disorder in a patient who may be susceptible to the disease or disorder but has not yet been diagnosed with the disease or disorder; (b) suppression of the symptoms of a disease, i.e., prevention of its development; or (c) alleviation of the symptoms of a disease, i.e., causing total or partial regression of the disease or symptoms.
[0175] The term "effective amount" or "therapeutically effective amount" refers to an amount of an active ingredient (such as a compound) that is sufficient to affect the treatment of a disease, disorder or symptom when administered to a subject to treat a disease, or at least one clinical symptom of a disease or condition. The term "therapeutically effective amount" may vary with the compound, the disease, disorder, and / or the symptoms of the disease or condition, the severity of the disease, disorder and / or the symptoms of the disease or condition, the age of the subject to be treated, and / or the weight of the subject to be treated. In any given case, the appropriate amount may be obvious to those skilled in the art, or may be determined by routine experimentation. In some embodiments, a "therapeutically effective amount" is an amount of at least one compound disclosed herein and / or at least one stereoisomer, tautomer or prodrug thereof and / or at least one pharmaceutically acceptable salt thereof that is effective to "treat" a disease or condition of a subject as defined herein. In the case of combination therapy, the term "therapeutically effective amount" refers to the total amount of a combination object used to effectively treat a disease, disorder or condition.
[0176] The term "disease" refers to any illness, ailment, ailment, symptom, or indication, and is interchangeable with the terms "disorder" or "condition."
[0177] Throughout the specification and the appended claims, unless the context requires otherwise, the term "comprise" and variations such as "comprises" and "comprising" are intended to specify the presence of the following features, but do not preclude the presence or addition of one or more other features. When used herein, the term "comprises" may be replaced by the terms "contains", "includes" or sometimes "has".
[0178] Throughout the specification and the appended claims, the term “C n-m " or "C n -C m " indicates a range including the endpoints, where n and m are integers and indicate the number of carbons. Examples include C 1-8 , C 1-6 , C1-C8, C1-C6, etc.
[0179] Unless otherwise stated, the percentages, ratios, proportions or parts used in this application are all by weight or volume. The amounts used in this application are by weight or volume. It can be easily determined by those skilled in the art.
[0180] Hereinafter, the present application will illustrate the beneficial effects of the present application by way of examples. Those skilled in the art will recognize that these examples are illustrative rather than restrictive. These examples will not limit the scope of the present application in any way. The experimental methods described in the following examples are conventional methods unless otherwise specified; the reagents and materials used are commercially available unless otherwise specified.
[0181] Unless specifically defined elsewhere in this document, all other technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0182] Example
[0183] The following examples are intended to be exemplary only and should not be considered to be limited in any way. Efforts have been made to ensure the accuracy of the numbers used (e.g., amounts, temperatures, etc.), but some experimental errors and deviations should be considered. Unless otherwise indicated, temperatures are in degrees Celsius. Reagents are purchased from commercial suppliers such as Sigma-Aldrich, Alfa Aesar, or TCI, and are used without further purification unless otherwise indicated. Unless otherwise indicated, the reactions set forth below are carried out in anhydrous solvents under a positive pressure of nitrogen or argon or with a drying tube; the reaction flask is equipped with a rubber septum for introducing substrates and reagents via a syringe; and the glassware is dried and / or heated to dryness.
[0184] 1 H NMR spectra were recorded on an Agilent instrument operating at 400 MHz. 1 HNMR
[0185] Spectra were obtained using CDCl3, CD2Cl2, CD3OD, D2O, d6-DMSO, d6-acetone or (CD3)2CO as solvents and tetramethylsilane (0.00 ppm) or residual solvent (CDCl3: 7.25 ppm; CD3OD: 3.31 ppm; D2O: 4.79 ppm; d6-DMSO: 2.50 ppm; d6-acetone: 2.05; (CD3)3CO: 2.05) as reference standards. When peak multiplicities are reported, the following abbreviations are used: s (singlet), d (doublet), t (triplet), q (quartet), qn (quintet), sx (sextet), m (multiplet), br (broad), dd (double of doublets), dt (double of triplets). Coupling constants are reported in Hertz (Hz) when given.
[0186] LCMS-1: LC-MS spectrometer (Agilent 1260 Infinity), detector: MWD (190-400 nm), mass detector: 6120SQ, mobile phase: A: water containing 0.1% formic acid, B: acetonitrile containing 0.1% formic acid, column: Poroshell 120EC-C18, 4.6×50 mm, 2.7 pm, gradient method: flow rate: 1.8 mL / min, time (min) A (%) B (%)
[0187]
[0188]
[0189] LCMS, LCMS-3: LC-MS spectrometer (Agilent 1260 Infinity II), detector: MWD (190-400 nm), mass detector: G6125C SQ, mobile phase: A: water containing 0.1% formic acid, B: acetonitrile containing 0.1% formic acid, column: Poroshell 120EC-C18, 4.6×50 mm, 2.7 pm, gradient method: flow rate: 1.8 mL / min, time (min) A (%) B (%)
[0190] Time (min) A(%) B(%) 0.00 95 5 1.5 5 95 2.0 5 95 2.1 95 5 3.0 95 5
[0191] LCMS-2: LC-MS spectrometer (Agilent 1290 Infinity II), detector: MWD (190-400 nm), mass detector: G6125C SQ, mobile phase: A: water containing 0.1% formic acid, B: acetonitrile containing 0.1% formic acid, column: Poroshell 120EC-C18, 4.6×50 mm, 2.7 pm, gradient method: flow rate: 1.2 mL / min, time (min) A (%) B (%)
[0192] Time (min) A(%) B(%) 0.00 90 10 1.5 5 95 2.0 5 95 2.1 90 10 3.0 90 10
[0193] Preparative HPLC was performed on a column (150 x 21.2 mm ID, 5 pm, Gemini NXC 18) with a flow rate of 20 ml / min, an injection volume of 2 ml, at room temperature and UV detection at 214 nm and 254 nm.
[0194] In the following examples, the following abbreviations are used:
[0195]
[0196]
[0197]
[0198]
[0199] Example 1: ((1S,3R)-3-(((5-bromo-2-nitrophenyl)amino)methyl)cyclopentyl)methanol
[0200] Step 1: 3-Oxabicyclo[3.2.1]octane-2,4-dione
[0201]
[0202] Cis-cyclopentane-1,3-dicarboxylic acid (100 g, 633 mmol) and Ac2O (600 ml) were placed in a 2 L round bottom flask equipped with a magnetic stirrer. The mixture was stirred at 140 °C for 12 hours. The mixture was concentrated under reduced pressure. The residue was wet-triturated with PE to give a crude product (70 g, 496.4 mmol, 78.5%). 1 H NMR (400MHz, DMSO) δ3.18(q,J=3.9Hz,2H),2.35(d,J=12.4Hz,1H),2.17–2.01(m,2H),1.90(t,J=7.5Hz,2H),1.69(dt,J=12.4,4.2Hz,1H).
[0203] Step 2: cis-3-Carbamoylcyclopentane-1-carboxylic acid
[0204]
[0205] A 2L round-bottom flask equipped with a magnetic stirrer was charged with (1R,5S)-3-oxabicyclo[3.2.1]octane-2,4-dione (70 g, 496.4 mmol), THF (700 ml) and NH3-MeOH 7M (4 equiv) at 0°C. The mixture was stirred at room temperature for 12 hours. The residue was quenched with MeOH (500 ml) at 0°C. The mixture was concentrated under reduced pressure to give a crude product (56 g, 354.4 mmol, 74.4%). [M+H] + =158.
[0206] Step 3: cis-3-carbamoylcyclopentane-1-carboxylic acid methyl ester
[0207]
[0208] A 1L round-bottom flask equipped with a magnetic stirrer was charged with cis-3-carbamoylcyclopentane-1-carboxylic acid (56 g, 354.4 mmol) and MeOH (600 mL). The temperature was lowered to 0°C, and H2SO4 (34.7 g, 354 mmol) was added dropwise to the mixture while maintaining the temperature at 0°C. The resulting mixture was stirred at room temperature for 12 hours. The mixture was concentrated under reduced pressure to give a crude product (49 g, 284.8 mmol, 80.3%). [M+H] + =172.
[0209] Step 4: ((cis)-3-(aminomethyl)cyclopentyl)methanol
[0210]
[0211] Cis-3-carbamoylcyclopentane-1-methyl carboxylate (49 g, 284.8 mmol) and THF (500 mL) were placed in a 1 L round-bottom flask equipped with a magnetic stirrer. The temperature was lowered to 0 ° C, and BH3-THF (1140 ml, 1140 mmol) was added dropwise to the mixture while maintaining the temperature at 0 ° C. The resulting mixture was stirred at room temperature for 24 hours. The residue was quenched with MeOH (500 ml) at 0 ° C. The mixture was concentrated under reduced pressure to give a crude product (35 g, 269.2 mmol, 79.5%). [M+H] + =130.
[0212] Step 5: ((cis)-3-(((5-bromo-2-nitrophenyl)amino)methyl)cyclopentyl)methanol
[0213]
[0214] A 1 L round bottom flask equipped with a magnetic stirrer was charged with ((cis)-3-(aminomethyl)cyclopentyl)methanol (35 g, 269.2 mmol), 4-bromo-2-fluoro-1-nitrobenzene (64.8 g, 295.9 mmol), DIEA (104.2 g, 807.8 mmol) and DMSO (500 mL). The mixture was stirred at 80 °C under N2 for 4 h. After cooling to room temperature, the mixture was poured into EA (500 mL), washed with brine (200 mL), water (3×200 mL), brine (200 mL), then dried over anhydrous Na2SO4 and concentrated in vacuo. The residue was purified by column chromatography (EA / PE, 24%) to give the title product (20 g, 60.8 mmol, 22.6%). [M+H] + =329.
[0215] Step 6: ((1S,3R)-3-(((5-bromo-2-nitrophenyl)amino)methyl)cyclopentyl)methanol
[0216]
[0217] The crude product (20 g) was purified by preparative SFC under the following conditions: ((Lux 3u Cellulose-34.6*50 mm, 3 μm), temperature: 35°C, flow (mL / min): 4, solvent A: CO2, solvent B: IPA (0.5% 2mM NH3-MeOH), gradient (B%): 10% to 50% in 2.0 min, maintained at 50% for 1.0 min, retention time 0.971 min) to give ((1S, 3R)-3-(((5-bromo-2-nitrophenyl)amino)methyl)cyclopentyl)methanol (5.6 g, 28.1%, ee=96.08%). [M+H] += 329. The crude product can also be purified by chiral HPLC under the following conditions: column (chiralpak IC-3 4.6 x 50 mm, 3 μm), mobile phase (Hex (0.1% DEA): EtOH = 80:20), flow rate 1.0 mL / min, temperature 25° C., retention time 2.836 min. 1 HNMR (300MHz, DMSO-d6) δ8.14(t,J=5.6Hz,1H),7.98(d,J=9.1Hz,1H),7.27(d,J=2.1Hz,1H),6.83(dd,J=9.1,2.0Hz,1H),4.45(t,J=5.3Hz,1H),4.34 (s,1H),3.43(s,1H),2.23(dt,J=15.3,7.5Hz,1H),2.11–1.83(m,2H),1.81 –1.54(m,1H),1.45–1.20(m,2H),1.06(t,J=7.0Hz,2H),1.00–0.71(m,1H).
[0218] Step 7: 2-(5-(((1S,3R)-3-(((5-bromo-2-nitrophenyl)amino)methyl)cyclopentyl)methoxy)-1- Methyl-1H-pyrazol-4-yl)-6-methylisonicotinate
[0219]
[0220] To a stirred solution of ((1S,3R)-3-(((5-bromo-2-nitrophenyl)amino)methyl)cyclopentyl)methanol (5.1 g, 15.5 mmol), methyl 2-(5-hydroxy-1-methyl-1H-pyrazol-4-yl)-6-methylisonicotinate (4.2 g, 17.0 mmol) and PPh3 (4.9 g, 18.6 mmol) in THF (100 mL) was added DIAD (3.8 g, 18.6 mmol). The mixture was then stirred at room temperature for 2 hours. The mixture was then concentrated and purified by silica gel column chromatography eluting with EtOAc / PE (0-80%) to give the product mixed with PPh3O (9.3 g); [M+H] + =558.3.
[0221] Step 8: 2-(5-(((1S,3R)-3-(((2-amino-5-bromophenyl)amino)methyl)cyclopentyl)methoxy)-1- Methyl-1H-pyrazol-4-yl)-6-methylisonicotinate
[0222]
[0223] To a stirred solution of methyl 2-(5-(((1S,3R)-3-(((5-bromo-2-nitrophenyl)amino)methyl)cyclopentyl)methoxy)-1-methyl-1H-pyrazol-4-yl)-6-methylisonicotinate (9.3 g, 16.7 mmol) in THF (100 mL) was added Raney nickel (4.5 g). The resulting mixture was stirred at room temperature for 2 hours under a hydrogen atmosphere (1 atm). The mixture was then filtered and the filtrate was concentrated. The resulting mixture (8.4 g) was used in the next step without purification. [M+H] + =528.3.
[0224] Step 9: 2-(5-(((1S,3R)-3-((6-bromo-2-imino-2,3-dihydro-1H-benzo[d]imidazol-1-yl) methyl)cyclopentyl)methoxy)-1-methyl-1H-pyrazol-4-yl)-6-methylisonicotinate
[0225]
[0226] A solution of methyl 2-(5-(((1S,3R)-3-(((2-amino-5-bromophenyl)amino)methyl)cyclopentyl)methoxy)-1-methyl-1H-pyrazol-4-yl)-6-methylisonicotinate (8.4 g, 15.9 mmol) and BrCN (2.5 g, 23.8 mmol) in MeOH (50 mL) was stirred at room temperature for 4 hours. The mixture was then concentrated and diluted with DCM (200 mL), and then washed with saturated aqueous NaHCO3 (3×100 mL) and brine (100 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with MeOH / DCM (0-15%) to give the product (7.1 g, 80.7%); [M+H] + =553.4.
[0227] Step 10: (7 1 R,7 3 S,E)-5 6 -Bromo-1 1 ,2 6 -Dimethyl-5- 2 ,5 3 -Dihydro-1 1 H,5 1 H-9-oxa-4-aza-5 (2,1)-Benzo[d]imidazole-2(2,4)-pyridine-1(4,5)-pyrazole-7(1,3)-cyclopentacyclononabi-3-one
[0228]
[0229] To a stirred solution of methyl 2-(5-(((1S,3R)-3-((6-bromo-2-imino-2,3-dihydro-1H-benzo[d]imidazol-1-yl)methyl)cyclopentyl)methoxy)-1-methyl-1H-pyrazol-4-yl)-6-methylisonicotinate (3.2 g, 5.8 mmol) in 80 mL of THF was added LiHMDS (1 N in THF, 14.5 mL) at room temperature for 15 minutes. The resulting mixture was stirred at room temperature for 1 hour. The mixture was then diluted with EA (100 mL), washed with saturated aqueous NH4Cl solution (2×100 mL) and brine (100 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was suspended in 100 mL of EA and stirred at room temperature for 1 hour. The mixture was then filtered to give the product (2.6 g, 86.2%); [M+H] + =521.2.
[0230] Example 2: (7 1 R,7 3 S,E)-1 1 ,2 6 -Dimethyl-5- 6 -(piperazin-1-yl)-5- 2 ,5 3 -Dihydro-1 1 H,5 1 H-9-Oxa-4-aza-5(2,1)-benzo[d]imidazole-2(2,4)-pyridine-1(4,5)-pyrazole-7(1,3)-cyclopentacyclic decalin-3-one
[0231] Step 1: 4-((7 1 R,7 3 S,E)-1 1 ,2 6 -Dimethyl-3-oxo-5- 2 ,5 3 -Dihydro-1 1 H,5 1 H-9-oxa-4-nitrogen Iso-5(2,1)-benzo[d]imidazole-2(2,4)-pyridine-1(4,5)-pyrazole-7(1,3)-cyclopentacyclonona-5 6 -yl)piperazine-1- Tert-Butyl Formate
[0232]
[0233] Example 1 (1.0 g, 1.92 mmol), tert-butyl piperazine-1-carboxylate (535 mg, 2.88 mmol), Pd2(dba)3 (360 mg, 0.4 mmol), Ruphos (360 mg, 0.8 mmol) and NaO t A solution of Bu (550 mg, 5.75 mmol) in DMA (30 mL) was stirred at 100° C. for 2 h. The reaction was concentrated in vacuo and the residue was purified by silica gel column (DCM:CH 3 OH=15:1) to give 4-(7 1 R,7 3 S,E)-1 1 ,2 6 -Dimethyl-3-oxo-5- 2 ,53 -Dihydro-1 1 H,5 1 H-9-oxa-4-aza-5(2,1)-benzo[d]imidazole-2(2,4)-pyridine-1(4,5)-pyrazole-7(1,3)-cyclopentacyclonona-5-nitropropane 6 -yl)piperazine-1-carboxylic acid tert-butyl ester (1.0 g, 83.2%). [M+H] + =627.
[0234] Step 2: (7 1 R,7 3 S,E)-1 1 ,2 6 -Dimethyl-5- 6 -(piperazin-1-yl)-5- 2 ,5 3 -Dihydro-1 1 H,5 1 H-9-oxa- 4-Aza-5(2,1)-benzo[d]imidazole-2(2,4)-pyridine-1(4,5)-pyrazole-7(1,3)-cyclopentacyclononabi-3-one
[0235]
[0236] To 4-((7 1 R,7 3 S,E)-1 1 ,2 6 -Dimethyl-3-oxo-5- 2 ,5 3 -Dihydro-1 1 H,5 1 H-9-oxa-4-aza-5(2,1)-benzo[d]imidazole-2(2,4)-pyridine-1(4,5)-pyrazole-7(1,3)-cyclopentacyclonona-5-nitropropane 6 To a mixture of tert-butyl)piperazine-1-carboxylate (1.0 g, 1.6 mmol) in DCM (20 mL) was added TFA (7 mL). The reaction mixture was stirred at room temperature for 2 hours, and the resulting mixture was concentrated in vacuo. The residue was treated with a saturated aqueous solution of NaHCO3 to pH = 7-8, and then extracted with DCM:MeOH (10:1) (100 mL×3). The combined organic phases were washed with brine (80 mL), dried over Na2SO4, filtered and concentrated in vacuo to give (7 1 R,7 3 S,E)-1 1 ,2 6 -Dimethyl-5- 6 -(piperazine-1-yl)-5 2 ,5 3 -Dihydro-1 1 H,5 1 H-9-oxa-4-aza-5(2,1)-benzo[d]imidazole-2(2,4)-pyridine-1(4,5)-pyrazole-7(1,3)-cyclopentacyclononaquinone-3-one (700 mg, 83.3%). [M+H] + =527.
[0237] Example 3: (7 1 R,7 3S,E)-5 6 -((S)-3-(methoxymethyl)piperazin-1-yl)-1 1 ,2 6 -Dimethyl-5- 2 ,5 3 -Dihydro-1 1 H,5 1 H-9-Oxa-4-aza-5(2,1)-benzo[d]imidazole-2(2,4)-pyridine-1(4,5)-pyrazole-7(1,3)-cyclopentacyclononaquinone-3-one
[0238]
[0239] The title compound was prepared in a similar manner to Example 2. [M+H] + =571.5
[0240] Example 4: (7 1 R,7 3 S,E)-1 1 ,2 6 -Dimethyl-5- 6 -(2-oxa-5,8-diazaspiro[3.5]nonan-5-yl)-5 2 ,5 3 -Dihydro-1 1 H,5 1 H-9-Oxa-4-aza-5(2,1)-benzo[d]imidazole-2(2,4)-pyridine-1(4,5)-pyrazole-7(1,3)-cyclopentacyclic decalin-3-one
[0241]
[0242] The title compound was prepared in a similar manner to Example 2. [M+H] + =569.5
[0243] Example 5: (7 1 S,7 3 R,E)-1 1 ,2 6 -Dimethyl-5- 6 -(piperazin-1-yl)-5- 2 ,5 3 -Dihydro-1 1 H,5 1 H-9-Oxa-4-aza-5(2,1)-benzo[d]imidazole-2(2,4)-pyridine-1(4,5)-pyrazole-7(1,3)-cyclopentacyclic decalin-3-one
[0244]
[0245] The title compound was prepared in a similar manner to Examples 1 and 2. [M+H] + =527.5
[0246] Example A: 3-(4-((3S,4R)-4-(4-((7 1 R,7 3 S,E)-1 1 ,2 6 -Dimethyl-3-oxo-5- 2 ,5 3 -Dihydro-1 1 H,5 1 H-9-oxa-4-aza-5(2,1)-benzo[d]imidazole-2(2,4)-pyridine-1(4,5)-pyrazole-7(1,3)-cyclopentacyclonona-5-nitropropane 6 -1-yl)piperazin-1-yl)-3-fluoropiperidin-1-yl)-3,3-dimethyl-2-oxoindolin-1-yl)piperidin-2,6-dione
[0247]
[0248] Step 1: N-(2,6-bis(benzyloxy)pyridin-3-yl)-2-(2,6-dibromophenyl)acetamide
[0249]
[0250] To a solution of 2-(2,6-dibromophenyl)acetic acid (10 g, 34.2 mmol), 2,6-bis(benzyloxy)pyridin-3-amine (11.5 g, 37.6 mml), DIEA (13.3 g, 102.6 mmol) in DMF (200 ml) was added HATU (19.5 g, 51.3 mmol) at 0°C. The mixture was stirred at room temperature overnight. The mixture was diluted with EA (500 mL) and then a solid filtrate was obtained. The mixture was concentrated under reduced pressure to give a crude product (15 g, 75.7%). [M+H] + =581.
[0251] Step 2: 1-(2,6-Bis(benzyloxy)pyridin-3-yl)-4-bromoindol-2-one
[0252]
[0253] A 500 mL round-bottom flask equipped with a magnetic stirrer was charged with N-(2,6-bis(benzyloxy)pyridin-3-yl)-2-(2,6-dibromophenyl)acetamide (15 g, 25.9 mmol), ((2-bromoethoxy)methyl)benzene (15.4 g, 71.5 mmol), K2CO3 (17.8 g, 129.5 mmol), CuCl (2.56 g, 25.9 mmol), pentane-2,4-dione (5.17 g, 51.8 mmol) and NMP (200 mL). The mixture was degassed in vacuo and purged with N2 three times. The resulting mixture was stirred at 85 °C under N2 for 3 hours. After cooling to room temperature, the mixture was diluted with ethyl acetate (300 mL) and then filtered through a celite pad. The filtrate was washed with brine (300 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EA / PE, 15%) to give the product (8.00 g, 61.8%). [M+H] + =501.
[0254] Step 3: 4-((3S,4R)-4-(4-benzylpiperazin-1-yl)-3-fluoropiperidin-1-yl)-1-(2,6-bis(benzyloxy) Pyridin-3-yl)indolin-2-one
[0255]
[0256] 1-(2,6-bis(benzyloxy)pyridin-3-yl)-4-bromoindolin-2-one (1 g, 2 mmol), 1-benzyl-4-((3S,4R)-3-fluoropiperidin-4-yl)piperazine (831 mg, 3 mmol, prepared in a manner similar to WO2023098656A1), t- A solution of BuONa (576 mg, 6 mmol) and Pd-PEPPSI-IPentCl (195 mg, 0.2 mmol) in DMA (15 mL) was degassed under reduced pressure and purged with N2 five times, and stirred at 90 ° C for 1 hour under N2. After cooling to room temperature, the mixture was diluted with DCM (100 mL) and then filtered through a celite pad. The filtrate was washed with brine (150 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (EA / PE, 40%) to give the product (810 mg, 60%). [M+H] + =698.3.
[0257] Step 4: 4-((3S,4R)-4-(4-benzylpiperazin-1-yl)-3-fluoropiperidin-1-yl)-1-(2,6-bis(benzyloxy) Pyridin-3-yl)-3,3-dimethylindolin-2-one
[0258]
[0259] DMF (10 mL) containing 4-((3S, 4R)-4-(4-benzylpiperazine-1-yl)-3-fluoropiperidin-1-yl)-1-(2,6-bis(benzyloxy)pyridin-3-yl)indolin-2-one (697 mg, 1 mmol) was stirred at 0 ° C under N2. NaH (100 mg, 2.5 mmol, 60% in oil) was added at this temperature. After 30 minutes, CH3I (355 mg, 2.5 mmol) was added and stirred at room temperature under N2 for 1 hour. The reaction solution was quenched with 20 mL of water and extracted with DCM. The organic layer was washed with brine, saturated aqueous sodium thiosulfate solution and water, and dried over anhydrous sodium sulfate. It was filtered and the resulting residue was concentrated and purified by using column chromatography (EA / PE, 40%) to give the product (500 mg, 69%). [M+H]+=726.5.
[0260] Step 5: 4-((3S,4R)-1-(1-(2,6-dioxopiperidin-3-yl)-3,3-dimethyl-2-oxoindoline- tert-Butyl 4-(3-fluoropiperidin-4-yl)piperazine-1-carboxylate
[0261]
[0262] Under N2, 4-((3S,4R)-4-(4-benzylpiperazin-1-yl)-3-fluoropiperidin-1-yl)-1-(2,6-bis(benzyloxy)pyridin-3-yl)-3,3-dimethylindol-2-one (726 mg, 1 mmol) was added to DMF / i- 10% Pd / C (100 mg) and (Boc)2O were added to a solution in PrOH (5 mL / 5 mL). The mixture was then exchanged with H2 twice and stirred under H2 atmosphere at 50°C for 15 hours. The mixture was filtered through a celite pad and washed with MeOH (50 mL). The filtrate was concentrated in vacuo to give the product (500 mg, 90%); [M+H] + =558.5.
[0263] Step 6: 3-(4-((3S,4R)-3-fluoro-4-(piperazin-1-yl)piperidin-1-yl)-3,3-dimethyl-2-oxoindole (doline-1-yl)piperidin-2,6-dione
[0264]
[0265] To a solution of tert-butyl 4-((3S,4R)-1-(1-(2,6-dioxopiperidin-3-yl)-3,3-dimethyl-2-oxoindolin-4-yl)-3-fluoropiperidin-4-yl)piperazine-1-carboxylate (279 mg, 0.5 mmol) in DCM (3 mL) was added TFA (1 mL). The reaction was stirred at room temperature for 2 hours and then concentrated in vacuo. The residue was dissolved in DCM (20 mL), washed with saturated NaHCO3 solution (3×20 mL) and brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give the product (180 mg, 78.6%); [M+H]+=458.5.
[0266] Step 7: 3-(4-((3S,4R)-4-(4-((7 1 R,7 3 S,E)-1 1 ,2 6 -Dimethyl-3-oxo-5- 2 ,5 3 -Dihydro- 1 1 H,5 1 H-9-oxa-4-aza-5(2,1)-benzo[d]imidazole-2(2,4)-pyridine-1(4,5)-pyrazole-7(1,3)-cyclopentane Renfan-5 6 -yl)piperazin-1-yl)-3-fluoropiperidin-1-yl)-3,3-dimethyl-2-oxoindolin-1-yl)piperidin-2,6-dimethyl ketone
[0267] Example 1 (104 mg, 0.2 mmol), 3-(4-((3S,4R)-3-fluoro-4-(piperazin-1-yl)piperidin-1-yl)-3,3-dimethyl-2-oxoindolin-1-yl)piperidine-2,6-dione (137 mg, 0.3 mmol), Pd2dba3 (36.6 mg, 0.04 mmol), Ruphos (36.8 mg, 0.08 mmol) and t- A mixture of BuONa (76.8 mg, 0.8 mmol) in DMA (5 mL) was stirred in a round-bottom flask at 90 ° C under N2 for 1 hour. Water (10 mL) was added and the mixture was extracted with DCM (20 mL×3). The combined organic layers were dried over Na2SO4. The solvent was removed by evaporation, and the residue was purified by silica gel column chromatography to give the product (40 mg, 22%). 1H NMR (500MHz, DMSO) δ12.43(s,1H),11.07(s,1H),8.53(s,1H),7.89(s,1H),7.45(s,1H),7.38(d,J=8.7Hz,1H),7.2 5(t,J=8.0Hz,1H),7.10–7.00(m,2H),6.95–6.90(m,1H),6.83(s,1H),5.25–5.21(m,1H),5.15–5.06(m,1H),4.38–4 .25(m,1H),4.22–4.16(m,1H),4.14–4.02(m,2H),3.74(s,3H),3.24–3.17(m,4H),3.15–2.97(m,2H),2.96–2.80(m, [M+H] + =898.6.
[0268] Example B: (R)-3-(4-(4-(4-(7 1 R,7 3 S,E)-1 1 ,2 6 -Dimethyl-3-oxo-5- 2 ,5 3 -Dihydro-1 1 H,5 1 H-9-oxa-4-aza-5(2,1)-benzo[d]imidazole-2(2,4)-pyridine-1(4,5)-pyrazole-7(1,3)-cyclopentanecyclononane-5 6 -yl)piperazin-1-yl)piperidin-1-yl)-2,6-difluorophenyl)piperidin-2,6-dione
[0269]
[0270] Step 1: 2,6-Bis(benzyloxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolidone Pyridine
[0271]
[0272] Four reactions were performed in parallel.
[0273] 4,4,5,5-tetramethyl-1,3,2-dioxaborane (760 g, 5.94 mol, 862 mL, 1.10 equiv) and TEA (1.09 kg, 10.8 mol, 1.50 L, 2.00 equiv) were added to a solution of 2,6-dibenzyloxy-3-bromo-pyridine (2.00 kg, 5.40 mol, 1.00 equiv) in dioxane (12.0 L), degassed and purged with N2, then Pd(PPh3)2Cl2 (189 g, 270 mmol, 0.05 equiv) was added to the mixture. The mixture was stirred at 90 ° C for 16 hours. The reaction mixture was filtered and concentrated. Four reactions were combined. The residue was purified by column chromatography (SiO2, petroleum ether / ethyl acetate = 1 / 0 to 0 / 1). 2,6-bis(benzyloxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)pyridine (5.80 kg, 13.9 mol, 64.3% yield) was obtained. [M+H] + =418.3
[0274] Step 2: 5-Bromo-1,3-difluoro-2-iodobenzene
[0275]
[0276] Five reactions were performed in parallel.
[0277] To a solution of 1-bromo-3,5-difluoro-benzene (1.00 kg, 5.18 mol, 595 mL) in THF (4.00 L) was added LDA (2 M, 2.59 L) at -70 °C. The mixture was stirred for 1 hour at -70 °C. A solution of I2 (1.33 kg, 5.23 mol, 1.05 L) in THF (1.00 L) was then added to the mixture at -70 °C. The mixture was stirred for 1 hour at -70 °C. The reaction mixture was poured into H2O (5.00 L), extracted with EtOAc (3.00 L×2), 5 reactions were combined, the combined organic layers were washed with brine (5.00 L), dried over Na2SO4, filtered and concentrated in vacuo at 40 °C to give a residue. The crude product was triturated with petroleum ether (6.00 L). The compound 5-bromo-1,3-difluoro-2-iodobenzene (4.50 kg, 14.1 mol, 54.4% yield) was obtained. [M+H] + =318.8.
[0278] Step 3: 2,6-Bis(benzyloxy)-3-(4-bromo-2,6-difluorophenyl)pyridine
[0279]
[0280] Pd(PPh3)4(1.63kg, 1.41mol), K3PO4(8.99kg, 42.3mol) were added to a solution of 5-bromo-1,3-difluoro-2-iodobenzene (4.50kg, 14.1mol) and 2,6-bis(benzyloxy)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (5.89kg, 14.1mol) in dioxane (22.5L) and H2O (4.50L). The mixture was stirred at 90°C for 12 hours. The mixture was filtered and the filtrate was extracted with EtOAc (5.00L), and the combined organics were washed with brine (5.00L), dried over Na2SO4, and concentrated in vacuo. The residue was purified by column chromatography (SiO2, petroleum ether:ethyl acetate=1:0 to 1:1). The compound 2,6-bis(benzyloxy)-3-(4-bromo-2,6-difluorophenyl)pyridine (3.00 kg, 6.01 mol, 42.5% yield, 96.5% purity) was obtained. 1 H NMR(400MHz,CHLOROFORM-d)7.47-7.40(m,1H),7.39-7.34(m,2H),7.34-7.29(m,2H),7.29-7.25(m ,4H),7.25-7.17(m,2H),7.12-7.05(m,2H),6.42(d,J=8.0Hz,1H),5.32(s,2H),5.28(s,2H);[M+H] + =482.1.
[0281] Step 4: 8-(4-(2,6-bis(benzyloxy)pyridin-3-yl)-3,5-difluorophenyl)-1,4-dioxa-8-azepine Spiro[4.5]decane
[0282]
[0283] To a solution of 2,6-bis(benzyloxy)-3-(4-bromo-2,6-difluorophenyl)pyridine (30 g, 62.24 mmol), 1,4-dioxa-8-azaspiro[4.5]decane (10.68 g, 74.69 mmol) and Cs2CO3 (40.58 g, 124.48 mmol) in 500 mL of dioxane was added Pd2(dba)3 (2.85 g, 3.11 mmol) and Xantphos (3.6 g, 6.22 mmol) under N2 atmosphere. The mixture was stirred at 80 °C for 16 hours under N2 protection. The mixture was diluted with EtOAc and filtered. The filtrate was concentrated in vacuo and purified by silica gel column chromatography (EA:PE=0-80%) to give a crude product. The crude material was recrystallized with MeOH and filtered. The filter cake was dried to give the title compound (26.8 g, 79% yield); [M+H] + =544.9.
[0284] Step 5: 3-(2,6-difluoro-4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)phenyl)piperidin-2,6-difluoro-4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)phenyl ketone
[0285]
[0286] To a solution of 8-(4-(2,6-bis(benzyloxy)pyridin-3-yl)-3,5-difluorophenyl)-1,4-dioxa-8-azaspiro[4.5]decane (26.8 g, 49.26 mmol) in 400 mL DMF and 80 mL iPrOH was added Pd / C (27 g, 10 wt.%, wet). The mixture was stirred at 45 °C under H2 atmosphere (4 bar) for 16 hours. The mixture was filtered and the filter cake was washed with DMF. The combined liquids were concentrated in vacuo to give the title compound (15 g, 83.2% yield); [M+H] + =367.1.
[0287] Step 6: (R)-3-(2,6-difluoro-4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)phenyl)piperidine-2-yl 6-Dione
[0288]
[0289] The title compound was purified by chiral HPLC (CHIRALPAK IF (2*25cm, 5um), MtBE (0.1% DEA): (MeOH: DCM = 1: 1) = 50: 50, 100 bar, 20ml / min), and the title compound corresponds to peak A at 0.990min / 254nm (4.47g, 12g racemate yield 37%); [M + H] + =367.1.
[0290] Step 7: (R)-3-(2,6-difluoro-4-(4-oxopiperidin-1-yl)phenyl)piperidine-2,6-dione
[0291]
[0292] (R)-3-(2,6-difluoro-4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)phenyl)piperidine-2,6-dione (1 g, 2.73 mmol) was placed in a 100 mL round-bottom flask with a magnetic stir bar. Then, 10 mL of 8N HCl aqueous solution was added. The mixture was stirred at room temperature for 30 minutes. The mixture was added dropwise to a saturated aqueous solution of NaHCO3, and finally, pH = 6-7. The liquid was extracted with DCM and separated. The organic phase was concentrated in vacuo and purified by silica gel column chromatography (MeOH:DCM = 0-5%) to give the title compound (850 mg, 96.7% yield); [M+H] + =323.1.
[0293] Step 8: (R)-3-(4-(4-(4-(7 1 R,7 3 S,E)-1 1 ,2 6 -Dimethyl-3-oxo-5- 2 ,5 3 -Dihydro-1 1 H, 5 1 H-9-oxa-4-aza-5(2,1)-benzo[d]imidazole-2(2,4)-pyridine-1(4,5)-pyrazole-7(1,3)-cyclopentane Nonane-5 6 -yl)piperazin-1-yl)piperidin-1-yl)-2,6-difluorophenyl)piperidin-2,6-dione
[0294] To a solution of Example 2 (80 mg, 0.15 mmol) and (R)-3-(2,6-difluoro-4-(4-oxopiperidin-1-yl)phenyl)piperidine-2,6-dione (68 mg, 0.21 mmol) in DCE (8 mL) was added STAB (95 mg, 0.45 mmol). The mixture was then stirred at 50 ° C overnight. The reactants were quenched with a saturated aqueous solution of NaHCO3 and extracted with DCM (3×15 m). The combined organic phases were washed with brine (1×10 mL), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column (DCM:CH3OH=10:1) and then purified by preparative HPLC chromatography to give the title product (33 mg, 26.1%). 1 HNMR(500MHz,DMSO)δ12.42(s,1H),10.87(s,1H),8.52(s,1H),7.89(s,1H),7.45(s,1H),7.36(d,J=8.7Hz,1H),7.01(s ,1H),6.90(d,J=8.7Hz,1H),6.66(s,1H),6.63(s,1H),4.30(s,1H),4.19(s,1H),4.05(dd,J=12.5,5.0Hz,3H),3.81(d, J=12.1Hz,2H),3.74(s,3H),3.16(s,4H),2.77(dd,J=15.1,7.7Hz,3H),2.68(s,4H),2.65–2.57(m,2H),2.55(s,3H),2. 53(d,J=4.0Hz,2H),2.49–2.40(m,2H),2.09(qd,J=13.4,4.9Hz,1H),1.99–1.79(m,6H),1.67(s,1H),1.54–1.43(m,2H). [M+H] + =833.7
[0295] Example C: 5-(3-(((S)-4-((7 1 R,7 3 S,E)-1 1 ,2 6 -Dimethyl-3-oxo-5- 2 ,5 3 -Dihydro-1 1 H,5 1H-9-oxa-4-aza-5(2,1)-benzo[d]imidazole-2(2,4)-pyridine-1(4,5)-pyrazole-7(1,3)-cyclopentacyclonona-5-nitropropane 6 -yl)-2-(methoxymethyl)piperazin-1-yl)methyl)azetidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
[0296]
[0297] Step 1: 2-(2,6-dioxopiperidin-3-yl)-5-(3-(hydroxymethyl)azetidin-1-yl)isoindoline- 1,3-Dione
[0298]
[0299] A mixture of 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindoline-1,3-dione (2.76 g, 1 mmol), azetidin-3-ylmethanol (870 mg, 1 mmol) and DIEA (2.85 g, 2 mmol) in DMSO (30 mL) was stirred in a round-bottom flask at 100 ° C under N2 for 12 hours. The mixture was diluted with H2O and extracted with EtOAc (100 mL×3). The combined organic layers were washed with brine (100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with CH2Cl2 / MeOH (10:1). 2-(2,6-dioxopiperidin-3-yl)-5-(3-(hydroxymethyl)azetidin-1-yl)isoindoline-1,3-dione (3 g, 87%) was obtained. [M+H] + =344.3
[0300] Step 2: 1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)azetidine- 3-Formaldehyde
[0301]
[0302] A mixture of 2-(2,6-dioxopiperidin-3-yl)-5-(3-(hydroxymethyl)azetidin-1-yl)isoindoline-1,3-dione (1.71 g, 0.5 mmol), 2-iodooxybenzoic acid (2.8 g, 1 mmol) in DMSO (15 mL) was stirred in a round-bottom flask at 25 ° C under N2 atmosphere for 12 hours. The mixture was diluted with H2O and extracted with DCM (100 mL×3). The combined organic layers were washed with brine (100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with CH2Cl2 / MeOH (10:1) to give the title compound (1.5 g, 88%). [M+H] +=342.3 Step 4: 5-(3-(((S)-4-((7 1 R,7 3 S,E)-1 1 ,2 6 -Dimethyl-3-oxo-5- 2 ,5 3 -Dihydro-1 1 H,5 1 H-9- Oxa-4-aza-5(2,1)-benzo[d]imidazole-2(2,4)-pyridine-1(4,5)-pyrazole-7(1,3)-cyclopentacyclonona-5 6 - 2-(2,6-dioxopiperidin-3-yl)isoindolyl)-2-(methoxymethyl)piperazin-1-yl)methyl)azetidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindolyl Indole-1,3-dione
[0303] To a solution of Example 3 (85 mg, 0.15 mmol) and 1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)azetidine-3-carbaldehyde (72 mg, 0.21 mmol) in DCE (6 mL) was added STAB (96 mg, 0.45 mmol). The mixture was then stirred at room temperature overnight. The reactants were quenched with a saturated aqueous solution of NaHCO3 (15 mL) and extracted with DCM (3×15 mL). The combined organic phases were washed with brine (1×10 mL), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (DCM:CH3OH=10:1) and then by preparative HPLC chromatography to give the title product (60 mg, 45%).
[0304] 1 H NMR (500MHz, DMSO) δ12.55(s,1H),11.08(s,1H),8.61(s,1H),7.99(s,1H),7.70(d,J=8.3Hz,1H),7.57(s,1H),7.43(d,J=8.7Hz,1H),7.13 (d,J=17.3Hz,1H),7.00(t,J=7.5Hz,1H),6.84(d,J=1.6Hz,1H),6.71(dd,J=8.4,1.9Hz,1H),5.07(dd,J=12.7,5.4Hz,1H),4.37–4.18(m,5 H),4.15–4.04(m,3H),3.88–3.81(m,10H),3.76–3.72(m,3H),3.69–3.62(m,2H),3.58–3.51(m,1H),3.48–3.42(m,1H),3.32–3.21(m,2H), 3.09–2.99(m,2H),2.94–2.84(m,1H),2.64–2.55(m,6H),2.06–1.99( m,1H),1.93–1.88(m,1H),1.84–1.79(m,2H),1.68–1.59(m,1H);[M+H] + =896.7.
[0305] Example D: (R)-3-(4-(4-(5-((7 1 R,7 3 S,E)-1 1 ,2 6-Dimethyl-3-oxo-5- 2 ,5 3 -Dihydro-1 1 H,5 1 H-9-oxa-4-aza-5(2,1)-benzo[d]imidazole-2(2,4)-pyridine-1(4,5)-pyrazole-7(1,3)-cyclopentanecyclononane-5 6 -yl)-2-oxa-5,8-diazaspiro[3.5]nonan-8-yl)piperidin-1-yl)-2,6-difluorophenyl)piperidin-2,6-dione
[0306]
[0307] The title compound was prepared in a manner analogous to Example B using Example 4 and (R)-3-(2,6-difluoro-4-(4-oxopiperidin-1-yl)phenyl)piperidine-2,6-dione. 1 H NMR (500MHz, DMSO) δ12.50(s,1H),10.87(s,1H),8.52(s,1H),7.89(s,1H),7.45(s,1H),7.40(d,J=8.5Hz,1H),7.02(s,1H),6.75(dd,J=8. 5,1.6Hz,1H),6.66(s,1H),6.63(s,1H),4.53(d,J=6.1Hz,2H),4.38(d,J=6.2Hz,2H),4.35–4.27(m,1H),4.19(t,J=8.2Hz,1H),4.10(t,J=8 .4Hz,1H),4.05(dd,J=12.6,5.1Hz,2H),3.80(d,J=12.5Hz,2H),3.74(s,3H),3.26–3.18(m,2H),2.99(s,2H),2.84–2.74(m,3H),2.65–2.5 1(m,7H),2.49–2.46(m,4H),2.09(qd,J=13.0,3.7Hz,1H),2.00–1.89(m,2H),1.83(d,J=10.1Hz,4H),1.75–1.66(m,1H),1.56–1.46(m,2H). [M+H] + =875.7.
[0308] Cellular p-EGFR inhibition assay
[0309] Cell treatment
[0310] On day 1, H1975-clone #23 (DEL19 / C797S) cells were plated at 3×10 410 cells / well were seeded in Corning 96-well plates (Cat. No. 3599) in cell culture medium [RPMI1640 (Gibco, Cat. No. 72400-047), 10% heat-inactivated FBS, 1% PS (Gibco, Cat. No. 10378)].
[0311] On day 2, BaF3-L858R cells were plated at 2 × 10 5 10 cells / well were seeded in a volume of 54 μl / well in a Corning 96-well plate (Cat. No. 3799) in cell culture medium [RPMI1640 (Gibco, without phenol red, Cat. No. 11835-030), 10% heat-inactivated FBS, 1% PS (Gibco, Cat. No. 10378)].
[0312] On day 2, H1975-#23 and BaF3-L858R cells were treated with compounds diluted in 0.1% DMSO cell culture medium and incubated for 16 h at 37°C, 5% CO2. The final concentration of compounds in all assays started at 10 uM and was diluted 5-fold for a total of 8 doses.
[0313] HTRF assay
[0314] After 16h treatment, for H1975-#23 cells, 50μl HTRF 1× lysis buffer was added to each well; for BaF3-L858R cells, 20μl 4× lysis buffer was added to each well; the plate was sealed and incubated on a plate shaker at room temperature for 1 hour; once the cells were lysed, 16μL of cell lysate was transferred to a PE 384-well HTRF detection plate; 4μL of premixed HTRF antibody was added to each well; the plate was covered with a plate sealer, rotated at 1000rpm for 1min, and incubated overnight at room temperature; read on a BMG PheraStar using the HTRF protocol (337nm-665nm-620nm).
[0315] The percent inhibition of the compound was calculated by the following equation: Percent Inhibition of Compound = 100-100 x (Signal - Low Control) / (High Control - Low Control), where Signal = each test compound group Low Control = lysis buffer only, no cells, indicating that p-EGFR was completely inhibited.
[0316] High Control = group of cells with DMSO added and no compound, indicating a microplate reading with no p-EGFR inhibition.
[0317] Imax is the maximum inhibition percentage.
[0318] IC of the compound 50 The value can be obtained by fitting the following equation:
[0319] Y = bottom value + (top value - bottom value) / (1 + ((IC 50 / X)^Hill slope))
[0320] Where X and Y are known values, IC 50 , Hillslope, top value and bottom value are parameters obtained by fitting with software. Y is the inhibition percentage (calculated by the equation), X is the concentration of the compound; IC 50 is the concentration of compound that achieves 50% inhibition. 50 The smaller the value, the stronger the inhibitory ability of the compound. 50 The higher the value, the weaker the inhibitory ability of the compound; Hill slope represents the slope of the fitting curve, usually about 1*; Bottom value represents the minimum value of the curve obtained by data fitting, usually 0% ± 20%; Top value represents the maximum value of the curve obtained by data fitting, usually 100% ± 20%. Experimental data were fitted by calculation and analysis using Dotmatics data analysis software.
[0321] Table 1. Degradation results of the examples (BaF3-L858R and H1975-Clone #8 (L858R / C797S))
[0322]
[0323] The foregoing examples and descriptions of certain embodiments should be considered illustrative rather than limiting of the invention as defined by the claims. It is readily understood that a variety of variations and combinations of the above features may be utilized without departing from the invention as set forth in the claims. All such variations are intended to be included within the scope of the present invention. All cited references are incorporated herein in their entirety by reference.
[0324] It will be appreciated that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms part of the common general knowledge in the art in any country.
Claims
1. A compound of formula (I): or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, or a tautomer thereof, or a deuterated analog thereof, or a prodrug thereof, in: R 1a , R 1b , R 2a and R 2b are each independently absent, hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy, -C 3-8 Cycloalkyl or -CN; each of the -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy or -C 3-8 Cycloalkyl is optionally selected from hydrogen, halogen, -C 1-8 Alkoxy, -C 3-8 substituted with at least one substituent of cycloalkyl or -CN; R 3 and R 4 are independently hydrogen, -C 1-6 Alkyl or -C 3-8 Cycloalkyl; each of the -C 1-6 Alkyl or -C 3-8 Cycloalkyl is optionally selected from hydrogen, halogen, -C 1-6 The alkoxy group is substituted with at least one substituent; R 7 are each independently absent, hydrogen, halogen, -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy, -C 3-8 Cycloalkyl or -CN; each of the -C 1-8 Alkyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, -C 1-8 Alkoxy or -C 3-8 Cycloalkyl is optionally selected from hydrogen, halogen, -C 1-8 Alkoxy, -C 3-8 cycloalkyl or -CN is substituted with at least one substituent; or Two R's 7 Together with the carbon atom to which it is attached, it forms a 3- to 12-membered ring, the ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent halogen, hydroxyl or -C1-C8 alkyl; R 8 and R 9 Each is independently selected from hydrogen, halogen, -C1-C6 alkyl or C3-C8 cycloalkyl; -C1-C6 alkyl or C3-C8 cycloalkyl are each optionally selected from hydrogen, halogen, -C 1-6 The alkoxy group is substituted with at least one substituent; R 10 Each independently selected from halogen, It is stated Each is optionally represented by at least one R 10a replace; The R 10a Each is independently absent, oxo (=O), halogen, hydroxy, -CN, -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl, C6-C 12 aryl or 5 to 12 membered heteroaryl; the -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, C3-C8 cycloalkyl, 3 to 8 membered heterocyclyl, C6-C 12 The aryl and 5- to 12-membered heteroaryl groups are each optionally substituted with at least one R 10b replace, R 10b are independently absent, oxo (=O), halogen, hydroxy, -CN, -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl, C6-C 12 Aryl or 5- to 12-membered heteroaryl; or Two R's 10a Together with the atoms to which it is attached, it forms a 3- to 12-membered ring, the ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent halogen, hydroxyl, -C1-C8 alkyl; At each occurrence, X 1 Each independently selected from -CR a or N; At each occurrence, X 2 are each independently selected from -NH- or -C(O)-; At each occurrence, X 3 Each independently selected from -NR a -, -O-, -S-, and -CR a R b -; At each occurrence, R a and R b Each is independently selected from hydrogen, hydroxy, halogen, CN, -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, -C3-C8 cycloalkyl, 3 to 8 membered heterocyclyl, -C6-C 12 The -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, -C3-C8 cycloalkyl, 3- to 8-membered heterocyclic, -C6-C 12 The aryl or 5 to 12 membered heteroaryl groups are each optionally substituted with at least one substituted group halogen, hydroxyl, halogen, -C1-C8 alkyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, -C3-C8 cycloalkyl, 3 to 8 membered heterocyclyl, -C6-C8 cycloalkyl, -C8-C8 cycloalkyl ... 12 aryl or 5- to 12-membered heteroaryl; or R a and R b The carbon atom to which it is attached forms a 3- to 12-membered ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituted halogen, hydroxyl, -C1-C8 alkyl, -C2-C8 alkenyl, -C2-C8 alkynyl, -C1-C8 alkoxy, -C2-C8 alkenyl, -C2-C8 alkynyl, C3-C8 cycloalkyl, 3- to 8-membered heterocyclyl, C6-C 12 aryl or 5- to 12-membered heteroaryl substituted; n1, n2, n3, n4 and n5 are each independently 0, 1, 2 or 3; s5, s6 and s7 are each independently 0, 1, 2 or 3.
2. The compound according to claim 1, wherein the compound is selected from the group consisting of formula (IIa), Preferably, the compound is selected from formula (IIb) and (IIc): Preferably, the compound is selected from formula (IId) and (IIe): Preferably, the compound is selected from formula (IIf) and (Ig): Where R 3 , R 4 , R 7 , R 8 , R 9 , R 10 , s5, s6 and s7 as defined in claim 1.
3. A compound as claimed in any one of the preceding claims, wherein R 1a , R 1b , R 2a and R 2b are each independently hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 alkynyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or -CN; wherein each of the methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, -C 2-8 Alkenyl, -C 2-8 Alkynyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl are optionally substituted with at least one substituent selected from hydrogen, F, Cl, Br, I, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or -CN; Preferably, R 1a , R 1b , R 2a and R 2b each independently represents hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -CF3, -CHF2, -CN, -CH2OCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH2CH2OCH2CH3; More preferably, R 1a , R 1b , R 2a and R 2b Each is independently hydrogen, F, Cl, methyl, methoxy, cyclopropyl, -CF3 or -CHF2, -CH2OCH3; More preferably, R 1a , R 1b , R 2a and R 2b are each independently hydrogen.
4. A compound as claimed in any one of the preceding claims, wherein R 3 and R 4 are each independently hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; the methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl being optionally substituted with at least one substituent selected from hydrogen, F, Cl, Br, I, methoxy, ethoxy, propoxy, butoxy, pentyloxy or hexyloxy; Preferably, R 3 and R 4 are each independently hydrogen, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; preferably, R 3 are independently methyl, and R 4 For hydrogen.
5. A compound as claimed in any one of the preceding claims, wherein R 7 each independently represents hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, heptyloxy, octyloxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, -CF3, -CHF2, -CN, -CH2OCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH2CH2OCH2CH3; Preferably, R 7 Each is independently hydrogen, F, Cl, methyl, methoxy, cyclopropyl, -CF3 or -CHF2, -CH2OCH3.
6. A compound as claimed in any one of the preceding claims, wherein two R 7 The carbon atom to which it is attached forms a 3-, 4-, 5-, 6-, 7- or 8-membered ring comprising 0-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; the ring is optionally substituted with at least one substituent F, Cl, Br, I, hydroxyl, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl or octyl; Preferably, the two R 7 The carbon atom to which it is attached forms a 3-, 4-, 5- or 6-membered ring, which is optionally substituted with at least one substituent F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl or octyl.
7. A compound as claimed in any one of the preceding claims, wherein R 8 and R 9 Each is independently selected from hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; the methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl is optionally substituted with at least one substituent selected from hydrogen, F, Cl, Br, I, methoxy, ethoxy, propoxy, butoxy, pentyloxy or hexyloxy; Preferably, R 8 and R 9 are each independently hydrogen, F, Cl, Br, I, methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; preferably, R 8 are independently hydrogen, and R 9 is F or methyl.
8. A compound as claimed in any one of the preceding claims, wherein R 10 Each independently selected from hydrogen, -F, -Cl, -Br, -I, It is stated Each is optionally represented by at least one R 10a replace; The R 10a R is each independently hydrogen, oxo (=O), F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, heptyl, octyl, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3-8 membered heterocyclyl, phenyl, or 5-12 membered heteroaryl; the methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyl, heptyl, octyl, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3-8 membered heterocyclyl, phenyl, and 5-12 membered heteroaryl are each optionally substituted by at least one R 10b replace, R 10b are independently oxo (═O), F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, -C2-C8 alkenyl, -C2-C8 alkynyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 3- to 8-membered heterocyclyl, phenyl, or 5- to 12-membered heteroaryl; or Two R's 10a Together with the carbon atoms to which they are attached, they form a 3, 4, 5, 6, 7 or 8 membered ring comprising 0, 1, 2 or 3 heteroatoms independently selected from nitrogen, oxygen or sulfur; said ring is optionally substituted with at least one substituent F, Cl, Br, I, hydroxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl or octyl; Preferably, R 10 Each independently selected from hydrogen, -F, -Cl, -Br, -I, 9. A compound as claimed in any one of the preceding claims, selected from
Citation Information
Patent Citations
Estrogen-related receptor alpha based protac compounds and associated methods of use
US20160045607A1
MDM2-based modulators of proteolysis and associated methods of use
US20170008904A1
Derivatives of 1-[(cyclopentyl or 2-pyrrolidinyl)carbonylaminomethyl]-4-(1,3-Thiazol-5-yl) benzene which are Useful for the Treatment of Proliferative, Autoimmune or Inflammatory Diseases
US20180050021A1
Indole derivatives as estrogen receptor degraders
US20180072711A1
Bifunctional molecules for degradation of EGFR and methods of use
US20190106417A1
Cited By
Macrocyclic compound for inhibiting and inducing EGFR (epidermal growth factor receptor) degradation, preparation method of macrocyclic compound and application of macrocyclic compound in medicine
CN122444752A
